<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-149535" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV-Related Endocrinopathies</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathi</surname>
            <given-names>Sri Ram Teja T.</given-names>
          </name>
          <aff>Einstein Medical center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sri Ram Teja Sathi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-149535.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>An estimated 37.9 million people were living with HIV at&#x000a0;the end of 2018, of which 24.7 million could access anti-retroviral therapy (ART). While HIV&#x000a0;was once considered a dreadful infection, the introduction of effective ART has transformed HIV into a chronic disease. Reducing HIV-related mortality with ART has meant an increased incidence of common health issues and conditions associated with aging, many of which have an endocrine basis. Individuals infected with HIV exhibit endocrine system dysfunction, ranging from subtle alterations in laboratory values without symptoms to overt glandular failure. Virtually every endocrine organ system can be involved. Although many of these changes can be seen with any significant systemic disease, some changes appear specific to HIV infection.</p>
        <p>During the early AIDS pandemic, endocrinopathic manifestations of HIV infection were mostly secondary to opportunistic infections and HIV-related neoplasms directly involving endocrine organs. However, with the widespread use of ART and the associated reduction in the incidence of the late manifestations of AIDS, much attention has been paid to endocrine dysfunction due to the direct effects of HIV infection, immune reconstitution, and the use of ART.<xref ref-type="bibr" rid="article-149535.r1">[1]</xref><xref ref-type="bibr" rid="article-149535.r2">[2]</xref></p>
      </sec>
      <sec id="article-149535.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>Similar to euthyroid sick syndrome, which is considered an adaptive response to any significant illness, advanced HIV disease can be associated with low tetraiodothyronine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) levels. However, the elevated reverse T<sub>3&#x000a0;</sub>(rT<sub>3</sub>) levels characteristic of&#x000a0;euthyroid sick syndrome may not be seen in advanced HIV disease.</p>
        <p>Neoplasms and opportunistic pathogens can invade endocrine organs and cause dysfunction.<xref ref-type="bibr" rid="article-149535.r3">[3]</xref><bold>&#x000a0;</bold>Kaposi sarcoma and lymphoma can infiltrate the thyroid gland, causing enlargement or destruction and hypothyroidism.<bold>&#x000a0;</bold><italic toggle="yes">Pneumocystis jiroveci</italic>&#x000a0;and <italic toggle="yes">Cryptococcus neoformans</italic> can invade the thyroid gland and cause&#x000a0;inflammatory thyroiditis, resulting in either hypo- or hyperthyroidism.&#x000a0;</p>
        <p>Medications used as a part of ART or&#x000a0;when&#x000a0;treating opportunistic infections, such as rifampin, phenytoin, ketoconazole, and ritonavir, can alter the clearance of thyroid hormones through the induction of hepatic microsomal enzymes.<xref ref-type="bibr" rid="article-149535.r4">[4]</xref>&#x000a0;Interferon-&#x003b1;, used to treat Kaposi sarcoma, has been associated with the development of autoimmune thyroiditis resulting in hypo- or hyperthyroidism. Immune reconstitution, a phenomenon of exaggerated immune response after the reversal of lymphopenia occurring after ART initiation, can induce various autoimmune diseases, including Graves disease.<xref ref-type="bibr" rid="article-149535.r5">[5]</xref><xref ref-type="bibr" rid="article-149535.r6">[6]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>HIV can cause adrenal insufficiency via direct involvement of the gland or the formation of anti-adrenal antibodies secondary to polyclonal B-lymphocyte activation. Individuals with HIV may also have elevated basal cortisol levels with normal or elevated adrenocorticotrophic hormone (ACTH) levels; this has been attributed to the stimulation of cortisol secretion by Interleukin 1 and tumor necrosis factor (TNF) and the stimulation of ACTH and corticotropin-releasing hormone (CRH) by Interleukins 1 and 6.<xref ref-type="bibr" rid="article-149535.r7">[7]</xref> The HIV envelope protein gp120 also increases cortisol. Interleukins 2 and 4 (IL-2, IL-4) and HIV-1 viral protein R (Vpr) increase sensitivity to cortisol.<xref ref-type="bibr" rid="article-149535.r8">[8]</xref><xref ref-type="bibr" rid="article-149535.r9">[9]</xref> It is unclear if this pattern of hypercortisolemia is a favorable adaptive response with anti-inflammatory properties or a harmful effect secondary to further immunosuppression.</p>
        <p>A syndrome of glucocorticoid resistance has been described in patients with HIV, characterized by elevated cortisol and normal or high ACTH levels with weakness, weight loss, and hyperpigmentation. This syndrome has been attributed to decreased receptor affinity for glucocorticoids. Individuals with HIV may have lower basal adrenal androgen levels and an elevated cortisol to dehydroepiandrosterone-sulfate (DHEA-S) ratio. DHEA-S levels decline as HIV progresses.<xref ref-type="bibr" rid="article-149535.r10">[10]</xref></p>
        <p>Adrenal gland involvement by opportunistic infections was common in the pre-ART era; more than 90% of untreated patients with HIV in an autopsy series were found to have cytomegalovirus-induced adrenalitis. Other organisms implicated in adrenal dysfunction include <italic toggle="yes">C neoformans</italic>, <italic toggle="yes">Mycobacterium avium-intracellulare</italic>, <italic toggle="yes">Mycobacterium tuberculosis</italic>,&#x000a0;<italic toggle="yes">P jiroveci</italic>, <italic toggle="yes">Histoplasma capsulatum</italic>, and <italic toggle="yes">Toxoplasma gondii</italic>. Kaposi sarcoma and lymphoma can also infiltrate the adrenal gland directly.<xref ref-type="bibr" rid="article-149535.r11">[11]</xref></p>
        <p>The antifungal ketoconazole reduces cortisol synthesis; phenytoin and rifampin accelerate steroid clearance. Megestrol acetate, used for HIV-related anorexia and muscle wasting, has intrinsic cortisol-like activity and can suppress the hypothalamic-pituitary-adrenal axis. The long-term use of megestrol can cause Cushing syndrome; its abrupt discontinuation can precipitate adrenal insufficiency. Some protease inhibitors reduce the metabolism of injected triamcinolone and inhaled glucocorticoids, like fluticasone and budesonide, leading to Cushing syndrome or adrenal insufficiency in the case of sudden medication discontinuation.<xref ref-type="bibr" rid="article-149535.r12">[12]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Individuals with HIV&#x000a0;may develop osteoporosis from chronic inflammation. HIV glycoprotein&#x000a0;GP120 induces T cells to produce a receptor-activator of nuclear factor-kappaB ligand (RANK-L); RANK-L activates osteoclasts and promotes bone resorption. The elevated levels of TNF-&#x003b1; and IL-1 seen in HIV infection also activate RANK-L.<xref ref-type="bibr" rid="article-149535.r13">[13]</xref><bold>&#x000a0;</bold>Additionally, patients infected with HIV frequently have a higher prevalence of the traditional risk factors for osteoporosis, including lower body weight, poor nutrition, tobacco and alcohol use, hypogonadism, and early menopause. Patients with HIV who are coinfected with hepatitis B or C have an increased fracture risk compared to patients infected only with HIV.</p>
        <p>Patients with HIV being treated with ART have an increased prevalence of reduced&#x000a0;bone mineral density&#x000a0;and osteoporosis than either matched controls or untreated HIV patients.<xref ref-type="bibr" rid="article-149535.r13">[13]</xref>&#x000a0;The rate of bone loss is the highest during the first 1 to 2 years after ART initiation and approaches the degree observed in patients using aromatase inhibitors or glucocorticoids. This rapid decrease in bone density has been attributed to immune reconstitution with the resultant upregulation of RANK-L&#x02013;mediated bone resorption. Tenofovir disoproxil fumarate is associated with a more significant loss of bone density in individuals with HIV; bone density improves with switching to a non&#x02013;tenofovir-based regimen. This decrease in bone density has also been observed in HIV-negative patients who take tenofovir disoproxil fumarate for prophylaxis.<xref ref-type="bibr" rid="article-149535.r14">[14]</xref></p>
        <p>Efavirenz has been associated with decreased serum vitamin D levels via its effects on vitamin D metabolism and binding protein. However, with long-term ART and viral suppression, bone density may increase and stabilize.<xref ref-type="bibr" rid="article-149535.r15">[15]</xref>&#x000a0;</p>
        <p>Tenofovir disoproxil fumarate and cidofovir, an antiviral used to treat cytomegalovirus (CMV), can cause proximal renal tubulopathy with resulting hypocalcemia and hypophosphatemia. Foscarnet, another antiviral used to treat CMV, can cause hypocalcemia by complexing with ionized calcium; it may also cause hypomagnesemia and hypokalemia through its effects on renal tubular absorption.<xref ref-type="bibr" rid="article-149535.r16">[16]</xref> The combination of foscarnet and pentamidine, a medication used to prevent and treat&#x000a0;<italic toggle="yes">P jiroveci</italic> pneumonia,&#x000a0;can cause severe hypocalcemia.<xref ref-type="bibr" rid="article-149535.r17">[17]</xref></p>
        <p>AIDS-related lymphoma and mycobacterial or&#x000a0;<italic toggle="yes">C neoformans&#x000a0;</italic>infections can cause hypercalcemia due to increased extrarenal activation of vitamin D by activated macrophages or tumor cells. Occasionally, hypercalcemia&#x000a0;may occur after initiating ART as part of an immune reconstitution syndrome.<xref ref-type="bibr" rid="article-149535.r18">[18]</xref></p>
        <p>
<bold>Gonadal Dysfunction&#x000a0;in Men</bold>
</p>
        <p>Low testosterone levels are&#x000a0;frequently observed in men with HIV. Secondary hypogonadism, or hypogonadotropic hypogonadism, characterized by low testosterone levels and inappropriately normal or low gonadotropin levels, is the most commonly observed type of gonadal dysfunction in individuals with HIV.<xref ref-type="bibr" rid="article-149535.r19">[19]</xref>&#x000a0;The etiology of this secondary hypogonadism is likely multifactorial. Chronic illness and weight loss, both observed in advanced HIV disease, are known causes of hypogonadotropic hypogonadism&#x000a0;through alteration of the hypothalamic-pituitary axis. The increased levels of IL-1 and TNF-&#x003b1; in HIV suppress the hypothalamic-pituitary axis and decrease testicular steroidogenesis. Direct invasion of the hypothalamus-pituitary unit by opportunistic central nervous system infections like <italic toggle="yes">T gondii</italic>, CMV, and C<italic toggle="yes">andida</italic>&#x000a0;spp can also occur in untreated advanced HIV.&#x000a0;</p>
        <p>Individuals with HIV are at an increased risk for malignancies requiring chemoradiation&#x000a0;that&#x000a0;can damage testicular cells&#x000a0;and cause primary hypogonadism. Primary hypogonadism, or hypergonadotropic hypogonadism, is characterized by low testosterone and elevated gonadotropin levels. Opportunistic infection of the testes by <italic toggle="yes">Mycobacteria&#x000a0;</italic>spp, <italic toggle="yes">Treponema pallidum</italic>, and fungi can also occur in advanced untreated HIV.&#x000a0;</p>
        <p>Various medications used to treat opportunistic infections can impair testosterone levels. Ketoconazole inhibits gonadal steroidogeneis. Glucocorticoids, megestrol acetate, and methadone can suppress the hypothalamic-pituitary-gonadal axis. Psychotropic medication-induced hyperprolactinemia&#x000a0;may&#x000a0;also reduce gonadotropin levels.<xref ref-type="bibr" rid="article-149535.r20">[20]</xref></p>
        <p>
<bold>Gonadal&#x000a0;Dysfunction in Women</bold>
</p>
        <p>Women with HIV are at an increased risk for anovulatory cycles and secondary amenorrhea due to disruption in the hypothalamic-pituitary-gonadal axis via mechanisms similar to those inducing secondary hypogonadism in men. Women with HIV also have lower levels of estradiol, testosterone, and DHEA-S than&#x000a0;women without HIV.</p>
        <p>Data regarding the influence of HIV on the onset of menopause is mixed. Many studies that showed an earlier onset of menopause in HIV-infected women relied on self-reported amenorrhea for more than 12 months to define menopause. However, prolonged secondary amenorrhea is common in HIV-infected women and can be falsely interpreted as menopause. Nevertheless, prolonged amenorrhea from anovulatory cycles or premature menopause may have similar health implications, such as effects on bone health and all-cause mortality.<xref ref-type="bibr" rid="article-149535.r21">[21]</xref><xref ref-type="bibr" rid="article-149535.r22">[22]</xref></p>
        <p>Contraception in HIV has received much attention. There are mixed data regarding depot medroxyprogesterone acetate potentially increasing susceptibility to acquiring HIV infection secondary to its glucocorticoid mimetic effects and effects on the vaginal epithelial lining. There is also some concern that ART regimens containing ritonavir may decrease the effectiveness of combined oral contraceptives.<xref ref-type="bibr" rid="article-149535.r23">[23]</xref></p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>Before the advent of ART, individuals with advanced HIV- and AIDS-related wasting syndrome were found to have elevated growth hormone (GH) and low insulin-like growth factor-1 (IGF-1) levels, suggesting a condition of GH resistance. These changes were not observed in HIV-infected patients without wasting syndromes.<xref ref-type="bibr" rid="article-149535.r24">[24]</xref></p>
        <p>HIV-related lipodystrophy became a commonly observed metabolic abnormality after the introduction of ART. GH axis dysfunction was investigated as a possible cause of lipodystrophy due to the known role of GH in promoting lipolysis, including that of visceral fat. Multiple studies using provocative testing with various cutoffs for GH levels showed a higher prevalence of biochemical GH deficiency in individuals with HIV than in controls; the clinical significance of this is unclear. Basal GH levels and the amplitude of GH pulses were lower in individuals with HIV with lipodystrophy than in individuals with HIV but no lipodystrophy and individuals without HIV. However, GH pulse frequency was similar in all groups. Several mechanistic causes of these findings have been suggested.<xref ref-type="bibr" rid="article-149535.r25">[25]</xref></p>
        <p>The percent increase in GH levels during provocative testing with&#x000a0;GH-releasing hormone and arginine (GHRH+ARG) is much higher than with GH alone in individuals with HIV lipodystrophy when compared to those without lipodystrophy and healthy controls;&#x000a0;arginine was a more potent stimulator of GH release in individuals with HIV lipodystrophy. Arginine provokes GH secretion&#x000a0;via inhibition of somatostatin tone, and these results suggest that individuals with HIV lipodystrophy have a higher baseline somatostatin tone as the cause of reduced GH secretion.<xref ref-type="bibr" rid="article-149535.r25">[25]</xref></p>
        <p>Free fatty acids (FFA) are known inhibitors of GH secretion. Individuals with HIV lipodystrophy have higher baseline FFA levels. Administering acipimox reduces circulating FFA and has more effectively increased GH levels during provocative testing of individuals with HIV lipodystrophy than in healthy controls. The natural GH secretagogue ghrelin is lower in individuals with HIV lipodystrophy than in healthy controls. ART may indirectly contribute to biochemical&#x000a0;GH deficiency by promoting visceral obesity, but as GH deficiency and visceral obesity promote each other, it is difficult to establish cause and effect. However, GH deficiency in individuals with HIV is not entirely explained by visceral obesity; the GH peak after GHRH+ARG stimulation was lower in patients with HIV than in HIV-negative patients with obesity of predominantly visceral fat. HIV positivity, with its associated chronic inflammatory state, premature aging, fat redistribution, and general health status, may all contribute to GH deficiency.<xref ref-type="bibr" rid="article-149535.r24">[24]</xref><xref ref-type="bibr" rid="article-149535.r26">[26]</xref></p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>"Wasting" is the involuntary loss of body weight and cellular mass. Weight loss or wasting was one of the most common AIDS-defining conditions before the introduction of ART. In addition to fat loss, wasting is characterized by a loss of predominately muscle mass&#x000a0;and is directly associated with increased mortality and morbidity. Various definitions&#x000a0;for these wasting syndromes include a greater than 10% loss in body weight since the&#x000a0;initial clinical visit, a decrease in body mass index (BMI) to&#x000a0;&#x0003c;20 kg/m<sup>2</sup> since the most recent prior visit,&#x000a0;or a greater than&#x000a0;5% loss in total body weight in 6 months, with the loss sustained for more than 1 year.<xref ref-type="bibr" rid="article-149535.r27">[27]</xref></p>
        <p>The&#x000a0;etiology of&#x000a0;AIDS-wasting syndrome is likely multifactorial and includes various adverse psychosocial and financial factors in addition to pathophysiologic ones. Patients with AIDS may have oropharyngoesophageal dysphagia and odynophagia secondary to opportunistic infection with CMV, herpetic infection, and <italic toggle="yes">Candida </italic>spp. Secondary opportunistic infections of the gastrointestinal tract may also result in malabsorption of nutrients.</p>
        <p>Normal GH levels are essential for maintaining protein balance and muscle mass. Patients with HIV- and AIDS-wasting syndromes routinely have elevated GH and low IGF-1 levels suggestive of GH resistance. Testosterone levels also correlate closely with lean muscle mass. Before the ART era, hypogonadism was the most frequently reported endocrinopathy in men with HIV. Greater than 67% of men with untreated HIV had symptoms suggestive of hypogonadism, and greater than 50% had low testosterone levels. Women with AIDS also have lower testosterone levels.<xref ref-type="bibr" rid="article-149535.r28">[28]</xref></p>
        <p>Additionally, patients with HIV are in a hypermetabolic state with an elevated resting energy expenditure mediated by IL-1, TNF, and interferon-&#x003b1;. The introduction of ART has not led to a&#x000a0;consistent reversal or reduction in the prevalence of HIV-associated weight loss.<xref ref-type="bibr" rid="article-149535.r29">[29]</xref><xref ref-type="bibr" rid="article-149535.r30">[30]</xref><xref ref-type="bibr" rid="article-149535.r31">[31]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Disorders of Fat Distribution, Glucose, and Lipid Metabolism</bold>
</p>
        <p>Before the introduction of ART, a wasting syndrome characterized by the loss of body muscle and fat and low cholesterol levels was the most commonly described metabolic abnormality in individuals with HIV. However, after the introduction and widespread use of ART, various abnormalities in body fat composition, glucose tolerance, and lipid metabolism were described. Initially, these clinical findings were grouped into a single syndrome similar to the metabolic syndrome called HIV lipodystrophy. HIV lipodystrophy was thought to be related to ART, particularly protease inhibitors. However, it soon became apparent that these metabolic abnormalities have a multifactorial origin and vary among patients.</p>
        <p>
<bold>Lipoatrophy and&#x000a0;Lipohypertrophy</bold>
</p>
        <p>Lipoatrophy is characterized by the diffuse loss of subcutaneous fat in the legs, buttocks, arms, and face; the lower body and face are commonly more severely affected. Lipoatrophy is distinct from HIV-wasting syndrome. Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), like stavudine and zidovudine, is the most significant risk factor for developing lipoatrophy; the risk is lower with other NTIs, like abacavir and tenofovir.<xref ref-type="bibr" rid="article-149535.r32">[32]</xref><xref ref-type="bibr" rid="article-149535.r33">[33]</xref><xref ref-type="bibr" rid="article-149535.r34">[34]</xref>&#x000a0;The pathophysiologic mechanism of NRTI-induced lipoatrophy is hypothesized to be underlying mitochondrial damage; NRTIs have a high affinity for the human mitochondrial DNA polymerase-&#x003b3;. Protease inhibitors (PIs) are not felt to cause lipoatrophy when used in isolation but may act synergistically when&#x000a0;paired with NRTIs.<xref ref-type="bibr" rid="article-149535.r35">[35]</xref>&#x000a0;Integrase inhibitors do not likely contribute to lipoatrophy.<xref ref-type="bibr" rid="article-149535.r36">[36]</xref><xref ref-type="bibr" rid="article-149535.r37">[37]</xref> Other factors predisposing to the development of lipoatrophy include advanced HIV disease, low CD4 lymphocyte&#x000a0;counts, male sex, and older age at ART initiation.</p>
        <p>The etiology and risk factors for lipohypertrophy, or excess fat accumulation, are less understood. Excessive fat accumulation in the abdomen, dorsocervical area, neck, and breasts has been widely described since the advent of ART. Initially,&#x000a0;PIs&#x000a0;were&#x000a0;thought to be primarily responsible for these clinical abnormalities. However, abnormal fat accumulation can develop in individuals never treated with PIs, and the risk does not appear elevated compared to other ART classes.<xref ref-type="bibr" rid="article-149535.r38">[38]</xref>&#x000a0;Host and disease factors such as increased age, higher baseline fat content, and low CD4 lymphocyte counts at ART initiation may increase the risk for fat accumulation.<xref ref-type="bibr" rid="article-149535.r39">[39]</xref></p>
        <p>
<bold>Glucose Intolerance and Diabetes Mellitus</bold>
</p>
        <p>"Prediabetes" or "glucose intolerance" describes abnormal carbohydrate metabolism in patients who do not meet the current diagnostic criteria for diabetes mellitus. Multiple studies have described an increased incidence of insulin resistance and diabetes mellitus in individuals with HIV.<xref ref-type="bibr" rid="article-149535.r40">[40]</xref> Several factors likely contribute to the apparent increased risk of abnormal carbohydrate metabolism. Even in individuals with HIV, the dominant risk factors for developing diabetes mellitus are traditional factors&#x000a0;such as increasing age, male sex, higher BMI, and non-White ethnicity. Improvement of HIV infection and restoration of health may be associated with weight gain, fat accumulation, and aging, all of which are associated with insulin resistance.<xref ref-type="bibr" rid="article-149535.r41">[41]</xref>&#x000a0;</p>
        <p>The lipoatrophy and lipohypertrophy seen in&#x000a0;individuals with HIV are strongly associated with&#x000a0;glucose intolerance, independent of total body weight. This may be due to decreased adiponectin levels increasing insulin resistance.<xref ref-type="bibr" rid="article-149535.r42">[42]</xref>&#x000a0;However, several ART drug classes are also known to contribute to glucose intolerance.</p>
        <p>PIs like ritonavir, lopinavir, and indinavir&#x000a0;are known to increase insulin resistance via possible blockade of the glucose transporter type-4 (GLUT-4). NRTIs such as zidovudine and stavudine can increase insulin resistance by affecting body composition and mitochondrial function.<xref ref-type="bibr" rid="article-149535.r43">[43]</xref>&#x000a0;Pentamidine can cause beta cell toxicity and acute hypoglycemia; individuals who develop hypoglycemia while taking pentamidine are at risk for developing diabetes mellitus in the long term.<xref ref-type="bibr" rid="article-149535.r44">[44]</xref>&#x000a0;Coinfection with hepatitis C further increases the risk of developing diabetes mellitus. The chronic inflammatory state has been shown to increase the risk of diabetes mellitus in the general population, and HIV infection causes chronic inflammation that does not entirely&#x000a0;abate even with effective ART.<xref ref-type="bibr" rid="article-149535.r45">[45]</xref>&#x000a0;</p>
        <p>
<bold>Lipid Abnormalities</bold>
</p>
        <p>Various lipid abnormalities are observed in individuals with HIV due to the infection, the use of ART, and changes in body composition. Patients with untreated HIV have elevated triglycerides and decreased low-density lipoproteins (LDL) and high-density lipoproteins (HDL). The degree of hypertriglyceridemia directly correlates with HIV RNA levels and may be secondary to viral inhibition of cholesterol efflux from macrophages.<xref ref-type="bibr" rid="article-149535.r46">[46]</xref><xref ref-type="bibr" rid="article-149535.r47">[47]</xref>&#x000a0;Lipoatrophy and lipohypertrophy are associated with an increase in triglycerides and a decrease in HDL.</p>
        <p>Several antiviral medications also contribute to dyslipidemia; these effects are particular to certain&#x000a0;pharmaceuticals and are not always class-specific.</p>
        <list list-type="bullet">
          <list-item>
            <p>Protease Inhibitors
<list list-type="bullet"><list-item><p>Ritonavir is associated with hypertriglyceridemia, which can be severe. Even low-dose ritonavir used as a "booster" with other protease inhibitors is associated with elevated LDL, total cholesterol, and triglycerides, albeit to a lower extent.<xref ref-type="bibr" rid="article-149535.r48">[48]</xref>&#x000a0;Ritonavir-boosted darunavir or atazanavir have less effect on serum lipids than ritonavir-boosted lopinavir.<xref ref-type="bibr" rid="article-149535.r49">[49]</xref><xref ref-type="bibr" rid="article-149535.r50">[50]</xref>&#x000a0;Switching to an atazanavir-containing regimen is associated with a decline in triglyceride and total cholesterol.<xref ref-type="bibr" rid="article-149535.r51">[51]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Non-nucleoside Reverse Transcriptase Inhibitors
<list list-type="bullet"><list-item><p>The non-nucleoside reverse transcriptase inhibitor (NNTRI) efavirenz is associated with increased triglycerides, total cholesterol, LDL, and HDL. Rilpivirine causes much lower increases in plasma lipids compared to efavirenz.<xref ref-type="bibr" rid="article-149535.r52">[52]</xref>&#x000a0;Etravirine&#x000a0;did not cause significant lipid abnormalities compared to placebo.<xref ref-type="bibr" rid="article-149535.r53">[53]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Nucleoside Reverse Transcriptase Inhibitors
<list list-type="bullet"><list-item><p>Tenofovir disoproxyl fumarate and emtricitabine are not associated with&#x000a0;adverse lipid profiles and, when combined, may have a mild lipid-lowering effect.<xref ref-type="bibr" rid="article-149535.r54">[54]</xref>&#x000a0;The newer formulation of tenofovir, tenofovir alafenamide, may cause an elevation in total cholesterol, LDL, and HDL not seen with the original formula.<xref ref-type="bibr" rid="article-149535.r55">[55]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Integrase Inhibitors
<list list-type="bullet"><list-item><p>All agents in this class are associated with a favorable lipid profile. Switching to an integrase inhibitor-containing regimen may decrease the levels of atherogenic lipids.<xref ref-type="bibr" rid="article-149535.r56">[56]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-149535.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>The prevalence of overt thyroid dysfunction in patients with HIV is equivalent to that of the general population at 1% to 3%. However, subclinical thyroid dysfunction&#x000a0;is significantly more common in patients with HIV, possibly as high as 12%. Subtle alterations in thyroid function tests can be seen in as many as 30% of individuals with HIV.<xref ref-type="bibr" rid="article-149535.r3">[3]</xref></p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>Before the introduction of ART, the prevalence of adrenal insufficiency in&#x000a0;individuals with HIV, mainly attributable to neoplasms and opportunistic infections, was estimated&#x000a0;between 5% and 10%.<xref ref-type="bibr" rid="article-149535.r11">[11]</xref>&#x000a0;Current estimates of adrenal dysfunction in patients with HIV are lower but are known to vary amongst different populations and geographic areas.</p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Patients with HIV have a 6.7-fold higher prevalence of decreased bone mineral density than the general population; the prevalence of frank osteoporosis is 3.7-fold higher.<xref ref-type="bibr" rid="article-149535.r13">[13]</xref>&#x000a0;Patients on ART have a 2.5-fold higher prevalence than those who are treatment-na&#x000ef;ve. Additionally, the risk of fragility fracture in patients with HIV is estimated to be 35% to 68% higher than that of the general population. This increased risk of fragility fracture is apparent almost&#x000a0;10 years earlier in individuals with HIV than in the general population.</p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>Before the introduction of ART, hypogonadism was the most frequently reported endocrinopathy in men with HIV. At that time, more than 67% of men had symptoms suggestive of hypogonadism, with more than 50% having low testosterone levels associated with weight loss, wasting, and low CD4 lymphocyte counts. Since the introduction of ART, various studies have estimated the prevalence of gonadal dysfunction in men with HIV between 13% and 40%. This wide estimate may be because of variations in the timing of blood draws and the assays employed.<xref ref-type="bibr" rid="article-149535.r19">[19]</xref><xref ref-type="bibr" rid="article-149535.r20">[20]</xref><xref ref-type="bibr" rid="article-149535.r57">[57]</xref></p>
        <p>Anovulation and amenorrhea can be seen in up to 50% of women with low CD4 lymphocyte counts.<xref ref-type="bibr" rid="article-149535.r58">[58]</xref>&#x000a0;As many as 50% of women with AIDS-wasting syndrome have low androgen levels.<xref ref-type="bibr" rid="article-149535.r59">[59]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>Most studies evaluating GH deficiency in patients with HIV have employed provocative testing with GHRH alone or GHRH+ARG. The prevalence of biochemical GH deficiency in all HIV-infected patients was&#x000a0;approximately 30% when a peak GH value cutoff of 7.5 to 9.0&#x000a0;&#x003bc;g/L was used. The prevalence of GH deficiency remained significantly elevated at 15% when a lower cutoff of 5 &#x003bc;g/L&#x000a0;was used. Even with a cutoff of 4.2 &#x003bc;g/L, the standard for non-HIV-infected patients with obesity, the prevalence of GH deficiency remains elevated at 10%.<xref ref-type="bibr" rid="article-149535.r24">[24]</xref></p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>Before the introduction of ART, approximately 30% of individuals with HIV were&#x000a0;noted to have tissue wasting, and weight loss&#x000a0;or wasting syndrome accounted for 18% of new diagnoses of AIDS. Studies evaluating weight loss and wasting performed after the introduction of ART have not consistently demonstrated the expected reversal or cessation of weight loss in individuals with HIV. A retrospective analysis of patients from 2012 to 2018 revealed the&#x000a0;cumulative prevalence of weight loss at 17.9% in patients on ART&#x000a0;and 19.1% in those not on ART.<xref ref-type="bibr" rid="article-149535.r29">[29]</xref><xref ref-type="bibr" rid="article-149535.r60">[60]</xref></p>
        <p>
<bold>Lipoatrophy and Lipohypertrophy</bold>
</p>
        <p>Estimates of the prevalence of fat distribution abnormalities in&#x000a0;individuals with HIV vary widely from 10% to 80% across studies, likely secondary to the lack of consensus about the definition of this syndrome and the methodology used for diagnosis. In a study of 452 individuals with HIV, the baseline prevalence of lipoatrophy, lipohypertrophy, and mixed forms was 35%, 44%, and 14%, respectively. After one year, 22% had new lipoatrophy, and 16% with baseline lipoatrophy no longer met the diagnostic criteria. At that same time, 23% developed new lipohypertrophy, and 15% of those with baseline lipohypertrophy experienced resolution.<xref ref-type="bibr" rid="article-149535.r61">[61]</xref>&#x000a0;</p>
        <p>
<bold>Glucose Intolerance and Diabetes Mellitus</bold>
</p>
        <p>The estimated prevalence of diabetes mellitus in individuals with HIV has varied widely, likely secondary to different baseline characteristics of the study cohorts and&#x000a0;varying&#x000a0;diagnostic criteria. A study of individuals with HIV in the United States&#x000a0;between&#x000a0;2009 and 2010&#x000a0;revealed a diabetes mellitus prevalence of 10.3%, rising to 14.1% after adjustment for common confounders in the general population.&#x000a0;In addition to age and obesity, the duration of HIV and mean CD4 lymphocyte count were also associated with diabetes mellitus.<xref ref-type="bibr" rid="article-149535.r40">[40]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Lipid Abnormalities</bold>
</p>
        <p>A study of patients aged greater than 70 years living with HIV found dyslipidemia&#x000a0;in&#x000a0;54% and cardiovascular disease in 23% of the 159 studied participants.<xref ref-type="bibr" rid="article-149535.r62">[62]</xref>&#x000a0;PIs have&#x000a0;been associated with dyslipidemia in 28% to 80% of patients taking&#x000a0;this medication.<xref ref-type="bibr" rid="article-149535.r20">[20]</xref></p>
      </sec>
      <sec id="article-149535.s4" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>Thyroid dysfunction may be subclinical or overt; subclinical dysfunction is, by definition, asymptomatic. Overt thyroid dysfunction may be due to a hypo- or hyperthyroid state.</p>
        <p>Patients with overt hypothyroidism may report dry skin, cold intolerance, constipation, and fatigue; the physical examination may reveal bradycardia, muscle weakness,&#x000a0;or delayed reflexes.<xref ref-type="bibr" rid="article-149535.r63">[63]</xref> Conversely, patients with hyperthyroidism may report heat intolerance, anxiety, palpitations, hyperdefecation, or frank diarrhea; the physical examination may reveal tachycardia, warm or moist skin, hyperreflexia, tremors, or lid retraction.<xref ref-type="bibr" rid="article-149535.r64">[64]</xref>&#x000a0;Muscle weakness, menstrual disturbances, and goiter may be seen in conjunction with any thyroid dysfunction. Graves disease may present with characteristic ophthalmopathy (see <bold>Image.</bold> Graves Orbitopathy.).<xref ref-type="bibr" rid="article-149535.r65">[65]</xref>&#x000a0;Destructive or infiltrative processes of the thyroid may be associated with local symptoms of pain and mass effect.</p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>Patients with chronic adrenal insufficiency present with unexplained fatigue, nausea, abdominal discomfort, anorexia, diffuse aches, weight loss,&#x000a0;or amenorrhea. If the patient has primary adrenal insufficiency, the physical examination may reveal hyperpigmentation of the vermilion borders, buccal mucosa, or palmar creases; hyperpigmentation may present as increased skin freckling. Acute adrenal insufficiency or adrenal crisis is usually precipitated by physiologic stress or underlying systemic illness and typically presents with profound hypotension with or without shock, hypoglycemia, fever, confusion, or coma.<xref ref-type="bibr" rid="article-149535.r66">[66]</xref><xref ref-type="bibr" rid="article-149535.r67">[67]</xref></p>
        <p>Patients with&#x000a0;hypercortisolemia or Cushing syndrome may present with weight gain, hair loss, easy bruising, muscle weakness, lethargy, depression, or decreased libido. A&#x000a0;physical examination may reveal plethoric facies, central obesity with thin extremities, a dorsocervical fat pad, purple abdominal striae, thin skin, or proximal muscle weakness.<xref ref-type="bibr" rid="article-149535.r68">[68]</xref></p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Decreased bone mineral density is typically asymptomatic. Patients with osteoporosis may also be asymptomatic until a fragility fracture occurs; fragility fractures occur in the setting of low-energy trauma, such as a fall from standing height or less. The hip and distal forearm are common sites of fragility fractures. Decreased height, stooped posture, or midline back pain may&#x000a0;indicate a vertebral compression fracture. However, osteoporosis also increases the frequency of non-fragility fractures.<xref ref-type="bibr" rid="article-149535.r69">[69]</xref></p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>Men with hypogonadism often report erectile dysfunction, weight loss, low energy levels, and decreased sexual desire; depression and cognitive dysfunction are less frequently endorsed.<xref ref-type="bibr" rid="article-149535.r70">[70]</xref>&#x000a0;If the hypogonadism is secondary to the involvement of the hypothalamic-pituitary unit by infections or neoplasms, symptoms such as headaches and visual disturbances may be present. The physical examination may reveal reduced muscle mass and a change in consistency or a decrease in the size of the testes. Gynecomastia may be present. A neurological exam, including an assessment of visual fields, should be&#x000a0;performed if a hypothalamic-pituitary lesion is suspected.</p>
        <p>In addition to secondary amenorrhea, women with decreased androgen levels may also report weight loss, fatigue, low mood, and low libido.&#x000a0;</p>
        <p>Individuals of both sexes with hypogonadism can present with low-energy trauma fractures from early-onset osteoporosis.&#x000a0;</p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>Children with GH deficiency can have poor growth velocity, delayed bone age, short stature, an increased weight-to-height ratio, and failure to thrive, especially in advanced HIV disease or AIDS. Adults with GH deficiency present with an increase in fat mass, particularly central adiposity, decreased lean muscle mass, reduced energy, and a&#x000a0;diminished&#x000a0;sense of well-being. The symptoms of GH deficiency are more severe if the onset of the disease occurs in childhood. The clinical manifestations of GH deficiency are nonspecific and may overlap&#x000a0;considerably&#x000a0;with those of HIV infection and generally poor health.<xref ref-type="bibr" rid="article-149535.r24">[24]</xref></p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>Individuals with AIDS-wasting syndrome present with weight loss, muscle weakness, and frequently poor overall health. They may report decreased appetite, dysphagia, odynophagia, diarrhea, and a history of opportunistic infections. The physical examination may reveal signs of weight loss and cachexia, such as temporal wasting and decreased skin fold thickness. Oropharyngeal mucous membranes should be evaluated for lesions suggestive of opportunistic infections from herpes simplex virus or <italic toggle="yes">Candida</italic> spp. Individuals with wasting syndromes and concurrent hypogonadism may have diminished sexual desire and erectile dysfunction. A&#x000a0;psychosocial assessment is indicated to identify additional barriers to adequate nutritional intake.<xref ref-type="bibr" rid="article-149535.r30">[30]</xref>&#x000a0;</p>
        <p>
<bold>Lipoatrophy and Lipohypertrophy</bold>
</p>
        <p>Lipoatrophy&#x000a0;is characterized by the loss of subcutaneous fat, preferentially in the face and extremities. Facial lipoatrophy results in the development of concave cheeks, periorbital hollowing, and visible facial musculature. Loss of subcutaneous fat in the extremities may make subcutaneous veins and musculature more prominent.</p>
        <p>Lipohypertrophy may result in a dorsocervical fat pad, lipomas, the enlargement of supraclavicular fat pads and anterior neck fat, and bilateral gynecomastia. A marked increase in abdominal girth secondary to&#x000a0;increased adiposity may occur;&#x000a0;the waist-to-hip ratio will increase accordingly. HIV-associated lipohypertrophy is predominantly secondary to increased visceral fat rather than subcutaneous fat. The inability to pinch subcutaneous fat between the fingers in the setting of increasing abdominal girth suggests visceral fat accumulation.<xref ref-type="bibr" rid="article-149535.r32">[32]</xref></p>
        <p>
<bold>Glucose Intolerance and Diabetes Mellitus</bold>
</p>
        <p>Individuals with diabetes mellitus can be asymptomatic, with a diagnosis made only by laboratory testing. Hyperglycemia can cause polyuria, polydipsia, visual disturbances, and symptoms of sensory neuropathy like numbness and tingling. The physical examination may reveal obesity or signs of insulin resistance like acanthosis nigricans. Long-standing untreated diabetes can also cause a catabolic state with significant weight loss.&#x000a0;&#x000a0;</p>
        <p>
<bold>Lipid Abnormalities</bold>
</p>
        <p>Mild to moderate elevations in lipids are usually not clinically evident and can only be detected with laboratory evaluations. Patients may have coexisting obesity, diabetes mellitus, and premature coronary artery disease. Severe hypertriglyceridemia may present with acute pancreatitis or xanthomas.<xref ref-type="bibr" rid="article-149535.r71">[71]</xref></p>
      </sec>
      <sec id="article-149535.s5" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>The cornerstone of the evaluation of thyroid function is the measurement of serum thyroid stimulating hormone (TSH) and free or total T<sub>4</sub> and T<sub>3</sub>.<xref ref-type="bibr" rid="article-149535.r72">[72]</xref>&#x000a0;Primary hypothyroidism is characterized by an elevated TSH and low T<sub>4</sub>, while primary hyperthyroidism is characterized by a low TSH and elevated T<sub>4</sub>, T<sub>3</sub>, or both. The TSH level is an unreliable diagnostic indicator in central or secondary hypothyroidism;&#x000a0;this diagnosis can be made if the T<sub>4</sub> is low in the proper clinical context. Thyroxine-binding globulin (TBG) levels correlate inversely with CD4 lymphocyte counts; this must be considered when interpreting total T<sub>4</sub> and total T<sub>3</sub> levels. Elevated levels of thyroid autoantibodies support a diagnosis of autoimmune thyroiditis as the cause of thyroid dysfunction.</p>
        <p>In a patient with the signs, symptoms, and laboratory results suggestive of hyperthyroidism but the absence of a clear diagnosis, radioactive iodine uptake testing may be beneficial; Graves disease is associated with increased uptake of iodine, and destructive or infiltrative thyroiditis reveals reduced or no uptake.&#x000a0;</p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>Diagnosing adrenal insufficiency in patients with HIV can be challenging; the presenting symptoms are frequently nonspecific and overlap those of HIV infection. Hyponatremia, hyperkalemia, and hypoglycemia are often seen in patients with adrenal insufficiency. Baseline cortisol levels can be elevated by HIV infection and, therefore, cannot be used reliably to rule out adrenal insufficiency. However, a morning cortisol level of less than 3 to 5 &#x000b5;g/dL highly suggests underlying adrenal insufficiency in all patients.<xref ref-type="bibr" rid="article-149535.r73">[73]</xref> A cortisol level&#x000a0;greater than 18&#x000a0;&#x000b5;g/dL 30 or 60 minutes after administration of 250 &#x000b5;g of cosyntropin makes adrenal insufficiency unlikely; cosyntropin is the first 24 amino acids of the N-terminal portion of the intact native ACTH molecule and comprises the biologically active region of intact ACTH. A lower diagnostic threshold for cortisol levels following cosyntropin administration of 14 to 15 &#x000b5;g/dL has been suggested when employing newer monoclonal antibody-based cortisol assays.<xref ref-type="bibr" rid="article-149535.r74">[74]</xref>&#x000a0; &#x000a0;</p>
        <p>Imaging is useful to evaluate the adrenal gland for neoplastic or infectious involvement. Adrenal gland enlargement may be seen in fungal infections and early tuberculosis. Adrenal glands may become small and fibrotic in late tuberculosis. Adrenal calcifications may be suggestive of tubercular disease.<xref ref-type="bibr" rid="article-149535.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Individuals with HIV should be periodically assessed for osteoporosis risk factors, and serum&#x000a0;vitamin D levels should be measured annually. All postmenopausal women, men aged 50 years or greater, and patients with other additional risk factors for osteoporosis should undergo&#x000a0;dual x-ray absorptiometry (DEXA) scanning.&#x000a0;Even when HIV is included in the risk factors for secondary osteoporosis or adjustment for Trabecular Bone Score (TBS) is made, the Fracture Risk Assessment Tool (FRAX) underestimates the risk of fracture in HIV-infected patients. Patients with documented osteopenia should be screened more regularly, and those with osteoporosis should strongly consider treatment.<xref ref-type="bibr" rid="article-149535.r15">[15]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>The evaluation of gonadal dysfunction in men hinges on establishing biochemical evidence of low testosterone levels. Serum testosterone should be checked in the early morning in a fasting state; testosterone levels fall naturally during the later part of the day and with food intake. The Endocrine Society recommends confirming low testosterone levels on at least 2 different days due to natural day-to-day variations. Most circulating testosterone is bound to sex hormone-binding globulin (SHBG); a minor fraction is loosely bound to albumin, and the&#x000a0;remainder is unbound or "free." Patients with HIV may have increased circulating SHBG, which can increase the total testosterone to within the normal range despite underlying hypogonadism. "Bioavailable testosterone" is the total of free&#x000a0;and&#x000a0;albumin-bound testosterone; this calculated value is considered a more accurate reflection of testosterone levels. The use of available direct analog-based free testosterone immunoassays is not recommended as they are inaccurate.<xref ref-type="bibr" rid="article-149535.r70">[70]</xref></p>
        <p>If low testosterone levels are associated with low or "inappropriately normal" gonadotropin levels, hypothalamic-pituitary dysfunction should be suspected, and further evaluation with sellar imaging and assessment for other pituitary hormonal deficiencies should be undertaken. However, elevated gonadotropin levels suggest primary testicular dysfunction or primary hypogonadism. These patients should be evaluated for Klinefelter syndrome and testicular involvement by opportunistic infections.&#x000a0;&#x000a0;</p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>Biochemical GH deficiency is defined as inadequate GH response to provocative testing. The GHRH+ARG stimulation test is the most studied provocative&#x000a0;test in HIV-infected patients, although the insulin tolerance test is considered the general diagnostic gold standard. An isolated IGF-1 level may be insufficient to diagnose GH deficiency but valuable when provocative test results are inconclusive.&#x000a0;</p>
        <p>A GH peak cutoff of 7.5&#x000a0;&#x003bc;g/L on provocative testing is the current&#x000a0;diagnostic standard of biochemical GH deficiency in HIV-infected patients. The clinical manifestations and markers of GH deficiency, such as quantification of visceral adiposity, bone mineral density, quality of life scores, and cardiovascular risk, were significantly different in patients on either side of this cutoff value.<xref ref-type="bibr" rid="article-149535.r24">[24]</xref>&#x000a0;A GH level above the cutoff essentially rules out GH deficiency.&#x000a0;&#x000a0;</p>
        <p>A diagnosis of GH deficiency should only be made when biochemical GH deficiency is documented in the appropriate clinical context;&#x000a0; multiple factors can influence the hormonal response to provocative testing. This is of particular importance in HIV-infected patients&#x000a0;in whom reduced GH secretion may be functional. When imaging reveals pituitary or hypothalamic injury or disease and laboratory testing reveals biochemical GH deficiency, true GH deficiency is highly likely.</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>The laboratory evaluation of patients with HIV- or AIDS-wasting syndromes is comprehensive. After the laboratory evaluation, imaging studies may be indicated to evaluate opportunistic infections and hormonal deficiencies.<xref ref-type="bibr" rid="article-149535.r30">[30]</xref> Recommended laboratory testing includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>CD4 lymphocyte count and HIV viral load to establish overall disease control and underlying risks for opportunistic infections</p>
          </list-item>
          <list-item>
            <p>Screening for nutritional deficiencies, including but not limited to iron, vitamin D, calcium, vitamin B12, and folate</p>
          </list-item>
          <list-item>
            <p>Testing for gastrointestinal opportunistic infections, as suggested by a comprehensive medical history and physical examination</p>
          </list-item>
          <list-item>
            <p>Evaluation for hypogonadism and growth hormone deficiency.</p>
          </list-item>
        </list>
        <p>
<bold>Lipodystrophy</bold>
</p>
        <p>The diagnosis of lipodystrophy is predominantly clinical; objective fat quantification via computed tomography, magnetic resonance imaging, or DEXA is limited to research settings.<xref ref-type="bibr" rid="article-149535.r32">[32]</xref>&#x000a0;Patients with HIV should be clinically evaluated for lipodystrophy at each clinic visit. Serial anthropometric measurements of height, weight, BMI, waist-to-hip ratio, limb circumference, and skin fold thickness are helpful. The diagnosis of lipodystrophy should prompt a more aggressive evaluation for other metabolic abnormalities, such as dyslipidemia and glucose intolerance, as these metabolic sequelae increase cardiovascular risk.<xref ref-type="bibr" rid="article-149535.r32">[32]</xref></p>
        <p>
<bold>Glucose Intolerance and Diabetes Mellitus</bold>
</p>
        <p>In the general population, diabetes mellitus may be diagnosed when fasting plasma glucose is &#x02265;126 mg/dL, 2-hour plasma glucose is &#x02265;200 mg/dL in a 75-gram oral glucose tolerance test, glycated hemoglobin (HbA1c) is &#x02265;6.5% or random plasma glucose is &#x02265;200 mg/dL in the presence of the classic symptoms of hyperglycemia. A prediabetes diagnosis requires a fasting plasma glucose of 100 to 125 mg/dL, a 2-hour plasma glucose of 140 to 199 mg/dL in a 75-gram oral glucose tolerance test, or HbA1c of 5.7% to 6.4%.</p>
        <p>The Infectious Disease Society of America (IDSA) recommends obtaining fasting plasma glucose and HbA1c before and within&#x000a0;3 months of initiating ART in&#x000a0;patients with HIV.<xref ref-type="bibr" rid="article-149535.r75">[75]</xref>&#x000a0;However, HbA1c may underestimate the glycemic burden in this population, and a cutoff of 5.8% may be more appropriate for diagnosis of diabetes mellitus.<xref ref-type="bibr" rid="article-149535.r76">[76]</xref><bold>&#x000a0;</bold>Once diagnosed, patients should be evaluated&#x000a0;for the micro- and macrovascular complications of diabetes mellitus at least annually.</p>
        <p>
<bold>Lipid Abnormalities</bold>
</p>
        <p>The principal implication of dyslipidemia is an increased risk of cardiovascular disease and associated mortality. The evaluation of patients with HIV and dyslipidemia should be individualized and include the assessment of traditional risk factors such as&#x000a0;any personal or family history of cardiovascular disease, individual dietary habits, physical activity levels, personal history of tobacco use, the presence and control of diabetes mellitus, laboratory evaluation of lipid levels, BMI, and waist circumference. The IDSA recommends obtaining a fasting lipid panel before and 3 months after initiating ART&#x000a0;with routine evaluation from then on.<xref ref-type="bibr" rid="article-149535.r35">[35]</xref>&#x000a0;Specific physical examination findings like tendon, skin, or palmar xanthomas, xanthelasmata, eruptive xanthomas, or lipemia retinalis should prompt an evaluation for an inherited lipid disorder.&#x000a0;</p>
      </sec>
      <sec id="article-149535.s6" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>The management of thyroid dysfunction in individuals with HIV is similar to that in those without the infection. The treatment of hypothyroidism entails supplementation with levothyroxine to achieve a serum TSH level between 0.5-2.5 mU/L.<xref ref-type="bibr" rid="article-149535.r72">[72]</xref> Management options for Graves disease include medical therapy with thionamides, radioactive iodine ablation, or surgical resection.<xref ref-type="bibr" rid="article-149535.r77">[77]</xref> Patients taking medications that can increase thyroid hormone clearance may require an increased dose of levothyroxine to achieve the desired physiologic response. Thyroid dysfunction secondary to neoplastic or opportunistic infectious infiltration may normalize with treating those disease processes.</p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>While the treatment of adrenal insufficiency can be life-saving in individuals with HIV, unnecessary treatment can exacerbate underlying infections and increase morbidity and mortality; establishing an accurate diagnosis is crucial. Hydrocortisone can be used in doses ranging from 15 to 30 mg/day in&#x000a0;2 or 3 divided doses. Fludrocortisone 0.05 to 0.2 mg/day can be used for concomitant mineralocorticoid deficiency in primary adrenal insufficiency. Patients should be evaluated regularly for excessive weight gain,&#x000a0;particularly the development of central obesity, dependent edema, and hypertension, and doses adjusted to prevent overtreatment.<xref ref-type="bibr" rid="article-149535.r67">[67]</xref></p>
        <p>Hydrocortisone doses should be increased to 2 or 3 times the baseline requirement during periods of physiologic stress, including minor illnesses, or when drugs that increase cortisol clearance, like rifampin or phenytoin, are used. Stress-dose steroids are required during severe illness, major surgery, or adrenal crisis; stress-dose steroids include hydrocortisone 100 mg orally followed by 50 mg orally every 6 hours or a continuous infusion of 200 mg over 24 hours.<xref ref-type="bibr" rid="article-149535.r66">[66]</xref>&#x000a0;</p>
        <p>Prednisone and dexamethasone are alternatives to hydrocortisone but carry a higher risk of iatrogenic steroid excess secondary to higher potency and longer duration of action. Dose adjustments may need to be considered for systemic and inhaled glucocorticoids with concomitant use of&#x000a0;PIs to reduce the risk of iatrogenic Cushing syndrome.</p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Patients with HIV and inadequate intake of dietary calcium should receive supplementation with 800 to 1200 mg of elemental calcium daily. Vitamin D should be supplemented to&#x000a0;achieve a serum vitamin D level &#x02265;30 ng/mL. Patients on ART with concomitant osteopenia or osteoporosis may benefit from switching to a bone-friendly&#x000a0;ART regimen that utilizes abacavir or tenofovir alafenamide instead of tenofovir disoproxyl fumarate. Bisphosphonates are the recommended pharmacologic therapeutic intervention for established osteoporosis. A single dose of zoledronic acid or alendronate&#x000a0;administered 2 weeks before initiating ART and continued for 14 weeks after that has been shown to attenuate the loss of bone mineral density commonly observed during the first two years after initiating ART. There is limited data on the use of denosumab and parathyroid hormone analogs in treating osteoporosis in individuals with HIV.<xref ref-type="bibr" rid="article-149535.r15">[15]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>Testosterone replacement therapy should be considered in men with symptoms of hypogonadism and unequivocally low testosterone levels. Testosterone replacement therapy has been shown to improve sexual function, lean muscle mass, mood, and bone mineral density. Commonly employed testosterone formulations include intramuscular or subcutaneous testosterone injections, transdermal patches, and gels. Short-term testosterone replacement therapy for 3 to 6 months can be an adjunctive treatment to achieve weight gain and muscle strength in patients with AIDS-wasting syndrome and low testosterone levels.<xref ref-type="bibr" rid="article-149535.r57">[57]</xref><xref ref-type="bibr" rid="article-149535.r70">[70]</xref>&#x000a0;</p>
        <p>Hormone replacement therapy with estrogen and progesterone should be considered for women with premature menopause or prolonged amenorrhea to counter the rapid decline in bone mineral density associated with these conditions.<xref ref-type="bibr" rid="article-149535.r59">[59]</xref>&#x000a0;</p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>The management of GH deficiency due to a primary pituitary or hypothalamic disease requires assessing other pituitary hormones, hormone replacement as needed, and disease-specific treatment. GH replacement is indicated for most patients whose onset of GH deficiency occurs in childhood and persists into adulthood. However, for patients with adult-onset GH deficiency, treatment decisions should be made via shared decision-making while considering the high cost and burden of treatment with relatively modest benefits.</p>
        <p>The true significance of reduced GH secretion in HIV-infected patients remains unclear. The studies that established reduced GH secretion in patients with HIV were performed almost exclusively in men and were not correlated with imaging of the pituitary or hypothalamic regions.<xref ref-type="bibr" rid="article-149535.r78">[78]</xref><xref ref-type="bibr" rid="article-149535.r79">[79]</xref> No trials have been conducted to investigate treating HIV-positive patients with biochemical GH deficiency with hormone replacement therapy.&#x000a0;</p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>The management of HIV- and AIDS-wasting syndromes requires diagnosing and treating contributing opportunistic infections and hormonal dysfunction while improving overall caloric intake. Appetite stimulants like dronabinol or megestrol acetate can be considered. Therapy with 0.1 mg/kg/d of r-hGH increases lean muscle mass and body weight.<xref ref-type="bibr" rid="article-149535.r30">[30]</xref><xref ref-type="bibr" rid="article-149535.r80">[80]</xref><xref ref-type="bibr" rid="article-149535.r81">[81]</xref> This regimen has been approved by the United States Food and Drug Administration (FDA) for AIDS-wasting syndrome. In patients with wasting and low testosterone levels, testosterone replacement therapy should be considered. Anabolic steroids like nandrolone have also been shown to increase lean muscle mass and strength.<xref ref-type="bibr" rid="article-149535.r30">[30]</xref>&#x000a0;</p>
        <p>
<bold>Lipoatrophy</bold>
</p>
        <p>Facial lipoatrophy may reveal the HIV status of an individual and result in social stigmatization. The fear of lipoatrophy may impact adherence to ART.&#x000a0;</p>
        <p>Substituting thymidine NRTIs like stavudine or zidovudine with another NRTI such as tenofovir or abacavir can increase subcutaneous fat but does not fully resolve peripheral lipoatrophy.<xref ref-type="bibr" rid="article-149535.r82">[82]</xref> There appears to be no benefit in switching PIS, nevirapine, or efavirenz.<xref ref-type="bibr" rid="article-149535.r83">[83]</xref><xref ref-type="bibr" rid="article-149535.r84">[84]</xref> Reconstructive therapy with autologous fat transplants, permanent fillers, or injectable bioabsorbable skin fillers, which stimulate local collagen production, is a therapeutic option for lipoatrophy.</p>
        <p>Thiazolidinediones, ligands for peroxisome proliferator activator reception gamma (PPAR&#x003b3;), promote adipocyte differentiation. Although they improved insulin sensitivity, there was no improvement in lipoatrophy.<xref ref-type="bibr" rid="article-149535.r82">[82]</xref><xref ref-type="bibr" rid="article-149535.r85">[85]</xref></p>
        <p>
<bold>Lipohypertrophy</bold>
</p>
        <p>The treatment of lipohypertrophy requires dietary modification and increased physical activity. Metformin may be used as a therapeutic intervention and is particularly beneficial in patients with insulin resistance. However, metformin can also reduce subcutaneous fat and should not be used when there is&#x000a0;coincident lipoatrophy.<xref ref-type="bibr" rid="article-149535.r82">[82]</xref></p>
        <p>HIV lipohypertrophy has been treated with GH and GHRH analogs.<xref ref-type="bibr" rid="article-149535.r86">[86]</xref>&#x000a0;Recombinant human growth hormone at supraphysiological dosages of 4 mg/d reduced visceral and subcutaneous fat; this regimen was frequently associated with adverse effects such as arthralgias, peripheral edema, carpal tunnel syndrome, and insulin resistance. Physiological doses of r-hGH were better tolerated, but the efficacy in reducing visceral fat was lower, and the effect was lost after treatment discontinuation.<xref ref-type="bibr" rid="article-149535.r86">[86]</xref>&#x000a0;</p>
        <p>Tesamorelin is a GHRH analog that increases the endogenous pulsatility of GH secretion, thereby limiting some of the adverse effects of high-dose exogenous GH. Tesamorelin is well-tolerated and can&#x000a0;decrease visceral adiposity without affecting subcutaneous fat or insulin sensitivity. While tesamorelin is the only FDA-approved drug approved to treat HIV lipohypertrophy, it is costly, and its benefits reverse when therapy is stopped.<xref ref-type="bibr" rid="article-149535.r87">[87]</xref><xref ref-type="bibr" rid="article-149535.r88">[88]</xref></p>
        <p>
<bold>Glucose Intolerance and Diabetes Mellitus</bold>
</p>
        <p>Managing diabetes mellitus in&#x000a0;individuals with HIV is similar to the general population. The target HbA1c for most patients with diabetes mellitus is&#x000a0;&#x02264;7%, but should be individualized for each patient. Managing hyperglycemia, preventing the micro- and macrovascular complications of diabetes, and reducing the overall risk of cardiovascular disease requires lifestyle modifications, dietary management, weight loss, and pharmacological therapy.<xref ref-type="bibr" rid="article-149535.r89">[89]</xref><xref ref-type="bibr" rid="article-149535.r90">[90]</xref><xref ref-type="bibr" rid="article-149535.r91">[91]</xref><bold>&#x000a0;</bold></p>
        <p>Patients taking ritonavir, lopinavir, zidovudine, or stavudine with concomitant persistent hyperglycemia despite therapeutic interventions may benefit from switching to an alternate ART regimen; this should only be considered after analyzing the potential of adverse effects and the impact on virological control. The HIV integrase inhibitor dolutegravir increases the concentration of metformin, and the total metformin dose should be limited to 1000 mg daily.<xref ref-type="bibr" rid="article-149535.r20">[20]</xref><bold>&#x000a0;</bold>The risk&#x000a0;of lactic acidosis with metformin increases with concomitant use of&#x000a0;NRTIs&#x000a0;like stavudine and didanosine.</p>
        <p>
<bold>Lipid Abnormalities</bold>
</p>
        <p>Managing lipid abnormalities in patients with HIV requires the regular assessment&#x000a0;and minimization of cardiovascular risk. Management of dyslipidemia should be comprehensive, and traditional risk factors like diet, smoking, and physical activity should be addressed at each visit. The management of concomitant diabetes mellitus and hypertension should be optimized. For patients on ART, switching their current regimen to one that is more lipid-friendly may be considered.<xref ref-type="bibr" rid="article-149535.r92">[92]</xref>&#x000a0;</p>
        <p>The decision to initiate pharmacotherapy for dyslipidemia can be made by employing multivariate models like the&#x000a0;American Heart Association/American College of Cardiology (AHA/ACC)&#x000a0;risk calculator and Data Collection on the Adverse Effects of Anti-HIV Drugs (DAD) risk calculator. However, these models typically underestimate the risk of dyslipidemia in patients with HIV.</p>
        <p>Statins are the drugs of choice when pharmacological therapy for dyslipidemia is warranted. Because of the potential for drug interactions with ART, the choice of statin should be carefully considered. Many statins are metabolized by CYP3A4, which is inhibited by&#x000a0;PIs and cobicistat, resulting in supratherapeutic statin concentrations and associated adverse effects.&#x000a0;</p>
        <p>However, CYP3A4 does not metabolize pitavastatin, pravastatin, or fluvastatin, and these medications can be safely used with various ART regimens.<xref ref-type="bibr" rid="article-149535.r93">[93]</xref>&#x000a0;In a recent study, pitavastatin demonstrated a decreased risk of cardiovascular complications in patients with HIV.<xref ref-type="bibr" rid="article-149535.r94">[94]</xref>&#x000a0;CYP3A4 also does not metabolize rosuvastatin, but, per the manufacturer, rosuvastatin levels can increase by 5- to 7-fold when it is used concomitantly with lopinavir-ritonavir or ritonavir-boosted atazanavir. If used with these ART regimens, rosuvastatin should be started at a low&#x000a0;dose of 5 or 10 mg.</p>
        <p>Atorvastatin is partially metabolized through&#x000a0;CYP3A4; atorvastatin levels can double when used with PIs. If atorvastatin is to be used in conjunction with PIs, it should be started at a lower dose, and dosages of 80 mg/d should be avoided. Simvastatin and lovastatin are highly metabolized through CYP3A4 and should not be used concomitantly with PIs.<xref ref-type="bibr" rid="article-149535.r95">[95]</xref></p>
        <p>Fibrates may be used to treat triglyceride elevations &#x0003e;500 mg/dL to reduce the risk of pancreatitis; fibrates have not been shown to improve the increased cardiovascular risk associated with hypertriglyceridemia.<xref ref-type="bibr" rid="article-149535.r96">[96]</xref> Fenofibrate is the most commonly used medication of this class due to its reduced propensity for drug interactions. On the other hand, omega-3 fatty acids may be used to manage hypertriglyceridemia with a good safety profile, and recent studies showed&#x000a0;they reduced&#x000a0;secondary ischemic episodes in patients with previous coronary artery disease.<xref ref-type="bibr" rid="article-149535.r97">[97]</xref></p>
      </sec>
      <sec id="article-149535.s7" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>The differential diagnosis of thyroid dysfunction in patients with HIV includes iodine deficiency, autoimmune thyroiditis unrelated to HIV infection, subacute granulomatous thyroiditis, painless thyroiditis, postpartum thyroiditis, Graves disease, toxic thyroid adenoma, and toxic multinodular goiter.<xref ref-type="bibr" rid="article-149535.r72">[72]</xref><xref ref-type="bibr" rid="article-149535.r98">[98]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>After a diagnosis of adrenal insufficiency is made in a patient with HIV, causes of secondary adrenal insufficiency must be considered. Secondary adrenal insufficiency may occur due to exogenous steroid use or involvement of the pituitary gland or hypothalamus by systemic diseases or local processes, including neoplasia, infections, and inflammatory disorders.<xref ref-type="bibr" rid="article-149535.r67">[67]</xref></p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Patients with HIV and a fragility fracture must have diagnoses such as malignancy, fibrous dysplasia, and other bony lesions excluded. Causes of secondary osteoporosis necessitate specific treatment and should also be excluded, including&#x000a0;hyperthyroidism, hyperparathyroidism, hypogonadism, Cushing syndrome, osteomalacia, inflammatory bowel disease, and malabsorption. A detailed review of prescription and nonprescription medications should be performed to identify drugs that can contribute to osteoporosis.<xref ref-type="bibr" rid="article-149535.r99">[99]</xref><xref ref-type="bibr" rid="article-149535.r100">[100]</xref></p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>The sexual dysfunction and other symptoms of hypogonadism in men are nonspecific. In addition to hypogonadism, factors such as HIV-related psychosocial issues, fear of HIV transmission, drug use, body image in AIDS-wasting syndrome, or lipodystrophy can all contribute to sexual dysfunction independent of testosterone levels.&#x000a0;</p>
        <p>Established adult-onset primary hypogonadism is most frequently due to Klinefelter syndrome, myotonic dystrophy, or bilateral varicoceles. Secondary hypogonadism may be secondary to morbid obesity, excessive alcohol use, critical illness, extreme weight loss unrelated to HIV, opiates, glucocorticoids, diabetes mellitus, hyperprolactinemia,&#x000a0;tumors, or inflammatory and infiltrative disorders of the hypothalamic-pituitary region.<xref ref-type="bibr" rid="article-149535.r57">[57]</xref></p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>Growth hormone deficiency can be caused by multiple disorders involving the pituitary and hypothalamus. These disorders include pituitary tumors; extra pituitary tumors such as craniopharyngioma or metastatic disease; infiltrative disorders&#x000a0;including Langerhans cell histiocytosis, sarcoidosis, or hemochromatosis; tubercular, bacterial, or fungal infections; hypophysitis; surgery or radiation of the sellar region; pituitary infarction or apoplexy;&#x000a0;cerebrovascular accidents including subarachnoid hemorrhage; and genetic&#x000a0;abnormalities causing congenital hormonal deficiencies.<xref ref-type="bibr" rid="article-149535.r101">[101]</xref>&#x000a0;</p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>Disorders of various organ systems can cause weight loss irrespective of HIV status. Malignancy is a common cause of weight loss, as are gastrointestinal malabsorptive disorders such as celiac disease. Several endocrinopathies, including hyperthyroidism and adrenal insufficiency, can induce profound weight loss. Advanced heart failure and end-stage renal disease may also cause wasting. Alcohol use disorder and substance use disorders, particularly involving stimulants such as cocaine, may also cause weight loss.</p>
        <p>
<bold>Lipoatrophy and Lipohypertrophy</bold>
</p>
        <p>The primary differential diagnosis for lipoatrophy is AIDS-wasting syndrome; other causes of unintentional weight loss or wasting should be considered. Weight gain due to common and rare conditions can mimic lipohypertrophy. These conditions include but are not limited to physical inactivity with excess calorie intake, endocrinopathies such as polycystic ovarian syndrome, hypothyroidism, and Cushing syndrome, and the use of medications such as antiepileptics, antipsychotics, and antidepressants.</p>
        <p>
<bold>Glucose Intolerance and Diabetes Mellitus</bold>
</p>
        <p>Diabetes mellitus can be secondary to disorders or drugs unrelated to HIV status that may need to be considered based on clinical suspicion.<xref ref-type="bibr" rid="article-149535.r102">[102]</xref>&#x000a0;Genetic disorders of pancreatic beta cell function or insulin action can induce glucose intolerance. Disorders affecting the exocrine pancreas, such as pancreatitis, cystic fibrosis, hemochromatosis, or malignancy, can cause glucose intolerance or frank diabetes. Cushing syndrome, acromegaly, and hyperthyroidism are common endocrinopathies that may cause glucose intolerance or frank diabetes mellitus. Glucose intolerance is a common adverse effect of prolonged antipsychotic, glucocorticoid, and thiazide use.</p>
        <p>
<bold>Lipid Abnormalities</bold>
</p>
        <p>The presence of severe hyperlipidemia and a strong family history of hyperlipidemia or premature cardiovascular disease should raise the clinical suspicion&#x000a0;of familial syndromes. Secondary causes of hyperlipidemia like diabetes mellitus, obesity, excessive alcohol consumption, hypothyroidism, nephrotic syndrome, chronic kidney disease, and medications like thiazides, beta blockers, glucocorticoids, estrogen preparations, and antipsychotics should also be considered.<xref ref-type="bibr" rid="article-149535.r103">[103]</xref></p>
      </sec>
      <sec id="article-149535.s8" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>With appropriate treatment, the prognosis of thyroid dysfunction in individuals with HIV is similar to those without HIV.&#x000a0;</p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>Treatment of adrenal insufficiency can be life-saving in patients with HIV. On the contrary, unnecessary treatment can exacerbate underlying infections and increase morbidity and mortality. As adrenal insufficiency is primarily secondary to opportunistic infections or neoplasia, its presence can signal advanced AIDS.<xref ref-type="bibr" rid="article-149535.r10">[10]</xref><xref ref-type="bibr" rid="article-149535.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>Fragility fractures occur about 10 years earlier in patients infected with HIV compared to the general population. Switching to a bone-friendly ART regimen reduces the rate of bone loss, but it is unknown if there is a decrease in fracture incidence. Treating osteoporosis in HIV-infected patients with bisphosphonates yields an&#x000a0;improvement in bone mineral density similar to that of&#x000a0;the general population; there have been no long-term studies to indicate&#x000a0;this reduces the incidence of fracture.&#x000a0;</p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>Hypogonadism in individuals with HIV who are not on ART can be a sign of advanced AIDS and an overall poor prognosis. However, outcomes may vary with the underlying cause of hypogonadism. Secondary hypogonadism from neoplastic or infectious involvement of the pituitary region may have a worse prognosis than most primary hypogonadism etiologies. Testosterone replacement therapy can positively affect quality of life by improving sexual function, mood, muscle mass and strength, and bone mineral density.<xref ref-type="bibr" rid="article-149535.r15">[15]</xref>&#x000a0;</p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>In general, replacing&#x000a0;GH in patients with true deficiency is associated with increased lean muscle mass, decreased fat mass, and improved quality of life. Improvement in bone mineral density with GH replacement was noted in men but not women for unclear reasons.<xref ref-type="bibr" rid="article-149535.r104">[104]</xref>&#x000a0;Studies of the effect of GH on lipid profiles revealed conflicting results. Improvement in specific cardiac function parameters, such as left ventricular mass and stroke volume, has been demonstrated,&#x000a0;but data on mortality is limited.<xref ref-type="bibr" rid="article-149535.r105">[105]</xref></p>
        <p>Patients with GH deficiency secondary to hypopituitarism have increased all-cause mortality that persists despite hormone replacement.<xref ref-type="bibr" rid="article-149535.r106">[106]</xref><xref ref-type="bibr" rid="article-149535.r107">[107]</xref>&#x000a0;There are no current studies investigating the treatment of individuals with HIV and biochemical GH deficiency with hormone replacement.&#x000a0;</p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>In patients with wasting syndromes, the magnitude of weight loss directly correlates with the risk of death. Despite a significant overall decrease in mortality associated with HIV&#x000a0;after the introduction of ART,&#x000a0; HIV-associated wasting remains a considerable concern. Even in patients on ART, weight loss of &#x0003e;10% from the baseline or previous visit is associated with a 4- to 6-fold increase in mortality.<xref ref-type="bibr" rid="article-149535.r108">[108]</xref></p>
        <p>
<bold>Disorders of Glucose and Lipid Metabolism and Fat Distribution</bold>
</p>
        <p>Individuals with HIV are at a higher risk for developing various metabolic abnormalities. This risk has been attributed directly to HIV, the natural course of the disease, and the use of ART.<xref ref-type="bibr" rid="article-149535.r109">[109]</xref> The increased incidence of metabolic complications increases the risk for atherosclerosis and associated cardiovascular complications. The Veterans Aging Cohort Study demonstrated a 50% increase in the risk of acute myocardial infarction in individuals with HIV compared to the non-HIV population over a 6-year study period.<xref ref-type="bibr" rid="article-149535.r110">[110]</xref>&#x000a0;ART has changed the course of the HIV pandemic and dramatically improved the lifespan of patients with HIV.<xref ref-type="bibr" rid="article-149535.r111">[111]</xref>&#x000a0;However, even with early treatment, a significant gap in life expectancy persists between individuals with and without HIV.<xref ref-type="bibr" rid="article-149535.r112">[112]</xref></p>
      </sec>
      <sec id="article-149535.s9" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Thyroid Dysfunction</bold>
</p>
        <p>Uncontrolled hypothyroidism&#x000a0;may cause anemia, electrolyte abnormalities, dyslipidemia, hypertension, and increased overall cardiovascular mortality. Myxedema coma is the result of severe, longstanding, untreated hypothyroidism, is characterized by symptoms secondary to decreased metabolism in multiple organs, and is associated with a high mortality rate.<xref ref-type="bibr" rid="article-149535.r113">[113]</xref>&#x000a0;</p>
        <p>The thyrotoxicosis of uncontrolled hyperthyroidism can cause arrhythmias, heart failure, and osteoporosis. Thyroid storm is a life-threatening thyrotoxic state frequently precipitated by another illness, surgery, or similar physiologic stressor.<xref ref-type="bibr" rid="article-149535.r114">[114]</xref></p>
        <p>All types of thyroid dysfunction can adversely affect menstrual cycles, fertility, and pregnancy outcomes.</p>
        <p>
<bold>Adrenal Dysfunction</bold>
</p>
        <p>Without adequate treatment, acute adrenal insufficiency causes death from cardiovascular collapse.<xref ref-type="bibr" rid="article-149535.r67">[67]</xref> Chronic adrenal insufficiency is associated with weight loss, its associated complications, and lower overall quality of life.<xref ref-type="bibr" rid="article-149535.r66">[66]</xref>&#x000a0;Cushing syndrome increases the risk of glucose intolerance, hypertension, hyperlipidemia, osteoporosis, and cardiovascular disease.</p>
        <p>
<bold>Bone Disorders and Osteoporosis</bold>
</p>
        <p>The most important clinical consequence of osteoporosis is a fracture. Vertebral fractures, followed by hip and forearm fractures, are the most commonly seen. Fractures are associated with significant pain, disability, reduced quality of life, and increased risk of all-cause mortality.<xref ref-type="bibr" rid="article-149535.r15">[15]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Gonadal Dysfunction</bold>
</p>
        <p>Hypogonadism is associated with sexual dysfunction, weight loss, a decreased sense of well-being, and overall poor quality of life. Hypogonadism causes osteoporosis and increases the risk of fragility fractures. Independent of HIV status, mortality is increased in men with hypogonadism. Data is mixed regarding a potential increase in overall cardiovascular risk with testosterone replacement therapy, especially in older men. In a recent randomized placebo-controlled trial, middle-aged and older men with a high risk for or known cardiovascular disease who received testosterone did not have a higher incidence of cardiovascular adverse events.<xref ref-type="bibr" rid="article-149535.r115">[115]</xref></p>
        <p>Testosterone replacement therapy can cause erythrocytosis, increase LDL, worsen sleep apnea, and increase the risk for venous thromboembolism. There is no definitive evidence that testosterone replacement&#x000a0;therapy increases the risk of developing prostate cancer. However, it is recommended that men 40 years and older with an elevated baseline risk of prostate cancer and all men older than 50 years should be monitored closely with serum prostate-specific antigen after initiating testosterone replacement therapy.&#x000a0;</p>
        <p>
<bold>Growth Hormone Deficiency</bold>
</p>
        <p>Patients with the onset of GH deficiency in childhood are at significantly increased risk of short stature. All patients with GH deficiency are at increased risk of reduced bone mineral density with resulting fractures, reduced lean muscle mass, and increased fat mass. Patients with GH deficiency routinely score lower on quality-of-life questionnaires than their healthy counterparts.<xref ref-type="bibr" rid="article-149535.r116">[116]</xref></p>
        <p>
<bold>Metabolic Dysfunction</bold>
</p>
        <p>
<bold>HIV- and AIDS-Wasting Syndromes</bold>
</p>
        <p>In addition to the increased risk of mortality, patients with these syndromes are at increased risk for nutritional deficiencies, osteoporosis,&#x000a0;and fractures. Patients with HIV- or AIDS-wasting syndromes consistently score lower on health-related quality-of-life measures.<xref ref-type="bibr" rid="article-149535.r30">[30]</xref>&#x000a0;</p>
        <p>
<bold>Disorders of Fat Distribution, Glucose, and Lipid Metabolism</bold>
</p>
        <p>Lipodystrophy is associated with dyslipidemia, insulin resistance, and chronic systemic inflammation, which can increase overall cardiovascular disease risk. Body fat distribution abnormalities&#x000a0;can lead to stigmatization, affecting self-esteem and quality of life.<xref ref-type="bibr" rid="article-149535.r32">[32]</xref>&#x000a0;</p>
        <p>The complications of diabetes mellitus are manifold and include cerebrovascular disease, cardiovascular disease, chronic kidney disease, peripheral vascular disease, and diabetic retinopathy. Dyslipidemia increases the risk of atherosclerosis and associated vascular complications.<xref ref-type="bibr" rid="article-149535.r117">[117]</xref> Severe hypertriglyceridemia can cause pancreatitis.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-149535.s10" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Individuals with HIV should be educated regarding their increased risk of endocrinologic dysfunction and cardiovascular disease. Despite HIV being an independent risk factor, traditional risk factors remain strong predictors of cardiovascular disease risk in this population. Hence, the optimal approach to cardiovascular risk reduction&#x000a0;includes lifestyle interventions such as smoking cessation, dietary intervention, physical activity, weight control, and avoidance of excessive alcohol consumption.&#x000a0;</p>
      </sec>
      <sec id="article-149535.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Individuals living with HIV are at an increased risk for developing&#x000a0;many endocrinopathies compared to the general population. The clinical presentation of hormonal dysfunction is frequently nonspecific and overlaps with that of HIV infection itself. A high index of clinical suspicion and careful coordination by primary care, infectious disease, cardiology, and endocrinology specialists is needed to diagnose and manage endocrinologic dysfunction appropriately.</p>
        <p>Measuring hormone levels is the most basic and indispensable part of evaluating any endocrine abnormality. An awareness of the unique effects of HIV status on hormone levels helps prevent misdiagnosis. Close attention should be paid to potential drug interactions between antiretrovirals and medications used to treat endocrinologic dysfunction. Pharmacists are indispensable in guiding patients and practitioners through various antiretroviral-induced adverse effects.</p>
        <p>Complications related to advanced HIV and immunocompromise are&#x000a0;no longer common in developed countries due to the widespread use of ART. However, HIV status and treatment with ART increase the risk for metabolic complications and cardiovascular disease. The currently available risk calculators underestimate the risk of cardiovascular disease despite considering HIV as an independent risk factor. This raises the need for aggressive preventative measures.&#x000a0;</p>
      </sec>
      <sec id="article-149535.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149535&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149535">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hiv-related-endocrinopathies/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=149535">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/149535/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=149535">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-149535.s13">
        <fig id="article-149535.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Graves orbitopathy Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="graves__orbitopathy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-149535.s14">
        <title>References</title>
        <ref id="article-149535.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ergin</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Inga</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Maung</surname>
                <given-names>TZ</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>HIV, Antiretroviral Therapy and Metabolic Alterations: A Review.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>May</month>
            <day>11</day>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e8059</fpage>
            <pub-id pub-id-type="pmid">32537277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>Antiretroviral Therapy Cohort Collaboration</collab>
            <article-title>Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.</article-title>
            <source>Lancet HIV</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>8</issue>
            <fpage>e349</fpage>
            <page-range>e349-e356</page-range>
            <pub-id pub-id-type="pmid">28501495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffmann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Thyroid function abnormalities in HIV-infected patients.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Aug</month>
            <day>15</day>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-94</page-range>
            <pub-id pub-id-type="pmid">17638201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zeitlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scourfield</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gazzard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stebbing</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2009</year>
            <month>Jan</month>
            <day>01</day>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-4</page-range>
            <pub-id pub-id-type="pmid">19092451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapembwa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Ruiter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Weetman</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>98</fpage>
            <page-range>98-106</page-range>
            <pub-id pub-id-type="pmid">15758839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Micali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russotto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Celesia</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pellican&#x000f2;</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Nunnari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Venanzi Rullo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Diseases and Thyroid Asymptomatic Dysfunction in People Living With HIV.</article-title>
            <source>Infect Dis Rep</source>
            <year>2022</year>
            <month>Sep</month>
            <day>01</day>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-667</page-range>
            <pub-id pub-id-type="pmid">36136821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Adrenal disorders in human immunodeficiency virus (HIV) infected patients.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>5-6</issue>
            <fpage>508</fpage>
            <page-range>508-14</page-range>
            <pub-id pub-id-type="pmid">24262982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nassoro</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mkhoi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sabi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Meremo</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lawala</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Mwakyula</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Insufficiency: A Forgotten Diagnosis in HIV/AIDS Patients in Developing Countries.</article-title>
            <source>Int J Endocrinol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>2342857</fpage>
            <pub-id pub-id-type="pmid">31341472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elenkov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Volpi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hiroi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Kino</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection.</article-title>
            <source>J Immunol</source>
            <year>2002</year>
            <month>Dec</month>
            <day>01</day>
            <volume>169</volume>
            <issue>11</issue>
            <fpage>6361</fpage>
            <page-range>6361-8</page-range>
            <pub-id pub-id-type="pmid">12444143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collazos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ibarra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adrenal function in the human immunodeficiency virus-infected patient.</article-title>
            <source>Arch Intern Med</source>
            <year>2002</year>
            <month>May</month>
            <day>27</day>
            <volume>162</volume>
            <issue>10</issue>
            <fpage>1095</fpage>
            <page-range>1095-8</page-range>
            <pub-id pub-id-type="pmid">12020177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Zapanti</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Hypothalamic-pituitary-adrenal axis in HIV infection and disease.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>791</fpage>
            <page-range>791-806</page-range>
            <pub-id pub-id-type="pmid">25169568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kearney</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daley-Yates</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Waldron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone.</article-title>
            <source>Sex Transm Infect</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>274</fpage>
            <pub-id pub-id-type="pmid">10615321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Qaqish</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.</article-title>
            <source>AIDS</source>
            <year>2006</year>
            <month>Nov</month>
            <day>14</day>
            <volume>20</volume>
            <issue>17</issue>
            <fpage>2165</fpage>
            <page-range>2165-74</page-range>
            <pub-id pub-id-type="pmid">17086056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baranek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.</article-title>
            <source>Antivir Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-32</page-range>
            <pub-id pub-id-type="pmid">32077867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biver</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis and HIV Infection.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2022</year>
            <month>May</month>
            <volume>110</volume>
            <issue>5</issue>
            <fpage>624</fpage>
            <page-range>624-640</page-range>
            <pub-id pub-id-type="pmid">35098324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gambertoglio</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Aweeka</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Causey</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Portale</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1991</year>
            <month>May</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>1130</fpage>
            <page-range>1130-5</page-range>
            <pub-id pub-id-type="pmid">1827127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuehn</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bogner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Obermaier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goebel</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;ndorff</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hypocalcaemia in HIV infection and AIDS.</article-title>
            <source>J Intern Med</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>245</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-73</page-range>
            <pub-id pub-id-type="pmid">10095819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Peluso</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bikle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shoback</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome.</article-title>
            <source>Bone Rep</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>10</volume>
            <fpage>100194</fpage>
            <pub-id pub-id-type="pmid">30627599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Hypogonadism in the HIV-Infected Man.</article-title>
            <source>Curr Treat Options Infect Dis</source>
            <year>2017</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <page-range>104-116</page-range>
            <pub-id pub-id-type="pmid">28344518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirza</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Luthra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chirch</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Endocrinological aspects of HIV infection.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>881</fpage>
            <page-range>881-899</page-range>
            <pub-id pub-id-type="pmid">29313284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conde</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Finotti</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Costa-Paiva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pinto-Neto</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>HIV, reproductive aging, and health implications in women: a literature review.</article-title>
            <source>Menopause</source>
            <year>2009</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>199</fpage>
            <page-range>199-213</page-range>
            <pub-id pub-id-type="pmid">18800017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cejtin</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Kalinowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bacchetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Massad</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Preston-Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anastos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moxley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minkoff</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction.</article-title>
            <source>Obstet Gynecol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>1423</fpage>
            <page-range>1423-31</page-range>
            <pub-id pub-id-type="pmid">17138776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yalamanchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dobs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Gonadal function and reproductive health in women with human immunodeficiency virus infection.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>731</fpage>
            <page-range>731-41</page-range>
            <pub-id pub-id-type="pmid">25169564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rochira</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guaraldi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Growth hormone deficiency and human immunodeficiency virus.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-111</page-range>
            <pub-id pub-id-type="pmid">28477736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanley</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Grinspoon</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>GH/GHRH axis in HIV lipodystrophy.</article-title>
            <source>Pituitary</source>
            <year>2009</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-52</page-range>
            <pub-id pub-id-type="pmid">18270841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Youssef</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sadera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mital</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>HIV and the Pituitary Gland: Clinical and Biochemical Presentations.</article-title>
            <source>J Lab Physicians</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-90</page-range>
            <pub-id pub-id-type="pmid">34054243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mangili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murman</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Zampini</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wanke</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Mar</month>
            <day>15</day>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>836</fpage>
            <page-range>836-42</page-range>
            <pub-id pub-id-type="pmid">16477562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wilkie</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dolan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallafent</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Aliabadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Grinspoon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight.</article-title>
            <source>Clin Infect Dis</source>
            <year>2003</year>
            <month>Feb</month>
            <day>15</day>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">12567309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Metabolic disturbances and wasting in the acquired immunodeficiency syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Jul</month>
            <day>30</day>
            <volume>327</volume>
            <issue>5</issue>
            <fpage>329</fpage>
            <page-range>329-37</page-range>
            <pub-id pub-id-type="pmid">1620172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemechek</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Polsky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Treatment guidelines for HIV-associated wasting.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>386</fpage>
            <page-range>386-94</page-range>
            <pub-id pub-id-type="pmid">10761494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wanke</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Forrester</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Speigelman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>803</fpage>
            <page-range>803-5</page-range>
            <pub-id pub-id-type="pmid">11017833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baril</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Junod</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dion</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Therrien</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laplante</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Falutz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>C&#x000f4;t&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000e9;bert</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Lalonde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lapointe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>L&#x000e9;vesque</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pinault</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tremblay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trottier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trottier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsoukas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated lipodystrophy syndrome: A review of clinical aspects.</article-title>
            <source>Can J Infect Dis Med Microbiol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>233</fpage>
            <page-range>233-43</page-range>
            <pub-id pub-id-type="pmid">18159551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Staszewski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pozniak</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>DeJesus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suleiman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Toole</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AK</given-names>
              </name>
              <collab>903 Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.</article-title>
            <source>JAMA</source>
            <year>2004</year>
            <month>Jul</month>
            <day>14</day>
            <volume>292</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-201</page-range>
            <pub-id pub-id-type="pmid">15249568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Podzamczer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gatell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fisac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lonca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Niubo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veloso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Llibre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barrufet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Merino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ribera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Lacasa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aranda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berenguer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delegido</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pedreira</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>L&#x000e9;rida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>del R&#x000ed;o</surname>
                <given-names>L</given-names>
              </name>
              <collab>ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team</collab>
            </person-group>
            <article-title>Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2007</year>
            <month>Feb</month>
            <day>01</day>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-47</page-range>
            <pub-id pub-id-type="pmid">17106274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wohl</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>McComsey</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tebas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Glesby</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Reeds</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shikuma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wininger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Revuelta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swindells</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fichtenbaum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Basar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tungsiripat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Weihe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wanke</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Sep</month>
            <day>01</day>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>645</fpage>
            <page-range>645-53</page-range>
            <pub-id pub-id-type="pmid">16886161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McComsey</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribaudo</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Paczuski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kelesidis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Apr</month>
            <day>01</day>
            <volume>62</volume>
            <issue>7</issue>
            <fpage>853</fpage>
            <page-range>853-62</page-range>
            <pub-id pub-id-type="pmid">26797215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Domingo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>Mdel M</given-names>
              </name>
              <name>
                <surname>Gallego-Escuredo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mateo</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Villarroya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de los Santos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Villarroya</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Estrada</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giralt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>e89088</fpage>
            <pub-id pub-id-type="pmid">24586518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shlay</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grunfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gibert</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Visnegarwala</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Raghavan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Farrough</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Kotler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>El-Sadr</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2007</year>
            <month>Apr</month>
            <day>15</day>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>506</fpage>
            <page-range>506-17</page-range>
            <pub-id pub-id-type="pmid">17325603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tolerability and safety of HIV protease inhibitors in adults.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>1111</fpage>
            <page-range>1111-24</page-range>
            <pub-id pub-id-type="pmid">15319670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernandez-Romieu</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Thompson-Paul</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Skarbinski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010.</article-title>
            <source>BMJ Open Diabetes Res Care</source>
            <year>2017</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>e000304</fpage>
            <pub-id pub-id-type="pmid">28191320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunfeld</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Insulin resistance in HIV infection: drugs, host responses, or restoration to health?</article-title>
            <source>Top HIV Med</source>
            <year>2008</year>
            <season>Jun-Jul</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-93</page-range>
            <pub-id pub-id-type="pmid">18591716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Addy</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gavrila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsiodras</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brodovicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karchmer</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Mantzoros</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>627</fpage>
            <page-range>627-36</page-range>
            <pub-id pub-id-type="pmid">12574192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tebas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2008</year>
            <month>Sep</month>
            <day>01</day>
            <volume>49 Suppl 2</volume>
            <fpage>S86</fpage>
            <page-range>S86-92</page-range>
            <pub-id pub-id-type="pmid">18725817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Dangerous and common drug interactions in patients with diabetes mellitus.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-802</page-range>
            <pub-id pub-id-type="pmid">11149162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Tassiopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Shikuma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McComsey</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.</article-title>
            <source>Diabetes Care</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>2244</fpage>
            <page-range>2244-9</page-range>
            <pub-id pub-id-type="pmid">20664016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doerrler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shigenaga</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1992</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>1045</fpage>
            <page-range>1045-52</page-range>
            <pub-id pub-id-type="pmid">1373735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mujawar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Pushkarsky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dubrovsky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mukhamedova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Orenstein</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bobryshev</surname>
                <given-names>YV</given-names>
              </name>
              <name>
                <surname>Bukrinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sviridov</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.</article-title>
            <source>PLoS Biol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>e365</fpage>
            <pub-id pub-id-type="pmid">17076584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shafran</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Mashinter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.</article-title>
            <source>HIV Med</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>421</fpage>
            <page-range>421-5</page-range>
            <pub-id pub-id-type="pmid">16268824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mills</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jayaweera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ruxrungtham</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cassetti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Workman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dierynck</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sekar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Abeele</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Lavreys</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.</article-title>
            <source>AIDS</source>
            <year>2009</year>
            <month>Aug</month>
            <day>24</day>
            <volume>23</volume>
            <issue>13</issue>
            <fpage>1679</fpage>
            <page-range>1679-88</page-range>
            <pub-id pub-id-type="pmid">19487905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petoumenos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>1878</fpage>
            <page-range>1878-88</page-range>
            <pub-id pub-id-type="pmid">20554568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gatell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salmon-Ceron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lazzarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Wijngaerden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Horban</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Odeshoo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van den Dungen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ledesma</surname>
                <given-names>E</given-names>
              </name>
              <collab>SWAN Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Jun</month>
            <day>01</day>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>1484</fpage>
            <page-range>1484-92</page-range>
            <pub-id pub-id-type="pmid">17479947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cahn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grinsztejn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lazzarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Supparatpinyo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Walmsley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crauwels</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rimsky</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Vanveggel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boven</surname>
                <given-names>K</given-names>
              </name>
              <collab>ECHO study group</collab>
            </person-group>
            <article-title>Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2011</year>
            <month>Jul</month>
            <day>16</day>
            <volume>378</volume>
            <issue>9787</issue>
            <fpage>238</fpage>
            <page-range>238-46</page-range>
            <pub-id pub-id-type="pmid">21763936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazzarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clotet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katlama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moll</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Towner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Trottier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vingerhoets</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Smedt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baeten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Beets</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woodfall</surname>
                <given-names>B</given-names>
              </name>
              <collab>DUET-2 study group</collab>
            </person-group>
            <article-title>Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Jul</month>
            <day>07</day>
            <volume>370</volume>
            <issue>9581</issue>
            <fpage>39</fpage>
            <page-range>39-48</page-range>
            <pub-id pub-id-type="pmid">17617271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crane</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Grunfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Willig</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Van Rompaey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lederman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kitahata</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.</article-title>
            <source>AIDS</source>
            <year>2011</year>
            <month>Jan</month>
            <day>14</day>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-95</page-range>
            <pub-id pub-id-type="pmid">21150555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mills</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crofoot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shalit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flamm</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gathe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scribner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shamblaw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callebaut</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Custodio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCallister</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2015</year>
            <month>Aug</month>
            <day>01</day>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-45</page-range>
            <pub-id pub-id-type="pmid">25867913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ofotokun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Landovitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ribaudo</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>McComsey</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aweeka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sagar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuritzkes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Para</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Leavitt</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Villasis-Keever</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baugh</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Lennox</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>JS</given-names>
              </name>
              <collab>AIDS Clinical Trials Group (ACTG) A5257 Team</collab>
            </person-group>
            <article-title>Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.</article-title>
            <source>Clin Infect Dis</source>
            <year>2015</year>
            <month>Jun</month>
            <day>15</day>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>1842</fpage>
            <page-range>1842-51</page-range>
            <pub-id pub-id-type="pmid">25767256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Vincentis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rochira</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Update on acquired hypogonadism in men living with HIV: pathogenesis, clinic, and treatment.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1201696</fpage>
            <pub-id pub-id-type="pmid">37455928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinha</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sengupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mukhopadhyay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus endocrinopathy.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-60</page-range>
            <pub-id pub-id-type="pmid">22028995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolan</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Grinspoon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Androgen deficiency and the role of testosterone administration in HIV-infected women.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>38 Suppl 1</volume>
            <fpage>S48</fpage>
            <page-range>S48-9</page-range>
            <pub-id pub-id-type="pmid">15867625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siddiqui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Samuel</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wirka</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Deering</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Harshaw</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harbour</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated wasting prevalence in the era of modern antiretroviral therapy.</article-title>
            <source>AIDS</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-135</page-range>
            <pub-id pub-id-type="pmid">34628440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spiegelman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wanke</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.</article-title>
            <source>Clin Infect Dis</source>
            <year>2005</year>
            <month>Jun</month>
            <day>15</day>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>1837</fpage>
            <page-range>1837-45</page-range>
            <pub-id pub-id-type="pmid">15909274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mothe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Podzamczer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ribera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vilad&#x000e9;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pedrol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Negredo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Molt&#x000f3;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paredes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Perez-Alvarez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gatell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Clotet</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain.</article-title>
            <source>Curr HIV Res</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>597</fpage>
            <page-range>597-600</page-range>
            <pub-id pub-id-type="pmid">19929794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heymann</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of thyroid disease.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>885</fpage>
            <page-range>885-902</page-range>
            <pub-id pub-id-type="pmid">1607406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness.</article-title>
            <source>Endocr Rev</source>
            <year>1983</year>
            <season>Fall</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>378</fpage>
            <page-range>378-88</page-range>
            <pub-id pub-id-type="pmid">6317368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Nistala</surname>
                <given-names>KRY</given-names>
              </name>
              <name>
                <surname>Ow</surname>
                <given-names>ZGW</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors of Thyroid Eye Disease.</article-title>
            <source>Endocr Pract</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-253</page-range>
            <pub-id pub-id-type="pmid">33655885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rushworth</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Torpy</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Falhammar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Crisis.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>29</day>
            <volume>381</volume>
            <issue>9</issue>
            <fpage>852</fpage>
            <page-range>852-861</page-range>
            <pub-id pub-id-type="pmid">31461595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husebye</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Krone</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>K&#x000e4;mpe</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Adrenal insufficiency.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Feb</month>
            <day>13</day>
            <volume>397</volume>
            <issue>10274</issue>
            <fpage>613</fpage>
            <page-range>613-629</page-range>
            <pub-id pub-id-type="pmid">33484633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fleseriu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cushing Syndrome: A Review.</article-title>
            <source>JAMA</source>
            <year>2023</year>
            <month>Jul</month>
            <day>11</day>
            <volume>330</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-181</page-range>
            <pub-id pub-id-type="pmid">37432427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svedbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hernlund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iverg&#x000e5;rd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Compston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stenmark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCloskey</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>J&#x000f6;nsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kanis</surname>
                <given-names>JA</given-names>
              </name>
              <collab>EU Review Panel of IOF</collab>
            </person-group>
            <article-title>Osteoporosis in the European Union: a compendium of country-specific reports.</article-title>
            <source>Arch Osteoporos</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <pub-id pub-id-type="pmid">24113838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Swerdloff</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Montori</surname>
                <given-names>VM</given-names>
              </name>
              <collab>Task Force, Endocrine Society</collab>
            </person-group>
            <article-title>Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>2536</fpage>
            <page-range>2536-59</page-range>
            <pub-id pub-id-type="pmid">20525905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sunkara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thandra</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Gaduputi</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies.</article-title>
            <source>Clin J Gastroenterol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>441</fpage>
            <page-range>441-448</page-range>
            <pub-id pub-id-type="pmid">29923163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garber</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cobin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gharib</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hennessey</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mechanick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Pessah-Pollack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Woeber</surname>
                <given-names>KA</given-names>
              </name>
              <collab>American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults</collab>
            </person-group>
            <article-title>Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.</article-title>
            <source>Endocr Pract</source>
            <year>2012</year>
            <season>Nov-Dec</season>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>988</fpage>
            <page-range>988-1028</page-range>
            <pub-id pub-id-type="pmid">23246686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deutschbein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Petersenn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test.</article-title>
            <source>Horm Metab Res</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>834</fpage>
            <page-range>834-9</page-range>
            <pub-id pub-id-type="pmid">19585406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YV</given-names>
              </name>
              <name>
                <surname>Povse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kerlin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shively</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oleksik</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>New Diagnostic Cutoffs for Adrenal Insufficiency After Cosyntropin Stimulation Using Abbott Architect Cortisol Immunoassay.</article-title>
            <source>Endocr Pract</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>684</fpage>
            <page-range>684-689</page-range>
            <pub-id pub-id-type="pmid">35487459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gallant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Emmanuel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zingman</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Horberg</surname>
                <given-names>MA</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-34</page-range>
            <pub-id pub-id-type="pmid">24235263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Georgoff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crum</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hadigan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A1C underestimates glycemia in HIV infection.</article-title>
            <source>Diabetes Care</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>1591</fpage>
            <page-range>1591-3</page-range>
            <pub-id pub-id-type="pmid">19502538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Management of Graves Thyroidal and Extrathyroidal Disease: An Update.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>3704</fpage>
            <page-range>3704-20</page-range>
            <pub-id pub-id-type="pmid">32929476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falutz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>517</fpage>
            <page-range>517-29</page-range>
            <pub-id pub-id-type="pmid">21663844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grinspoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gelato</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Editorial: The rational use of growth hormone in HIV-infected patients.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>8</issue>
            <fpage>3478</fpage>
            <page-range>3478-9</page-range>
            <pub-id pub-id-type="pmid">11502766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engelson</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Glesby</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mendez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Albu</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heymsfield</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kotler</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2002</year>
            <month>Aug</month>
            <day>01</day>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-91</page-range>
            <pub-id pub-id-type="pmid">12138344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schambelan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grunfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Daar</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>LaMarca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kotler</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bozzette</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Breitmeyer</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.</article-title>
            <source>Ann Intern Med</source>
            <year>1996</year>
            <month>Dec</month>
            <day>01</day>
            <volume>125</volume>
            <issue>11</issue>
            <fpage>873</fpage>
            <page-range>873-82</page-range>
            <pub-id pub-id-type="pmid">8967667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moyle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sutinen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Managing HIV lipoatrophy.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Feb</month>
            <day>07</day>
            <volume>363</volume>
            <issue>9407</issue>
            <fpage>412</fpage>
            <page-range>412-4</page-range>
            <pub-id pub-id-type="pmid">14962517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arnaiz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Podzamczer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ribera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knobel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Riera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pedrol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Force</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Llibre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Segura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Richart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cort&#x000e9;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Javaloyas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aranda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cruceta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Lazzari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gatell</surname>
                <given-names>JM</given-names>
              </name>
              <collab>Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team</collab>
            </person-group>
            <article-title>Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Sep</month>
            <day>11</day>
            <volume>349</volume>
            <issue>11</issue>
            <fpage>1036</fpage>
            <page-range>1036-46</page-range>
            <pub-id pub-id-type="pmid">12968087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Workman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DA</given-names>
              </name>
              <collab>Mitochondrial Toxicity (MITOX) Study Group</collab>
            </person-group>
            <article-title>Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>Jul</month>
            <day>10</day>
            <volume>288</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-15</page-range>
            <pub-id pub-id-type="pmid">12095385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arioglu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duncan-Morin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sebring</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rother</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herion</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Premkumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sumner</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reitman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.</article-title>
            <source>Ann Intern Med</source>
            <year>2000</year>
            <month>Aug</month>
            <day>15</day>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-74</page-range>
            <pub-id pub-id-type="pmid">10929166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivakumar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mechanic</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fehmie</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.</article-title>
            <source>HIV Med</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>453</fpage>
            <page-range>453-62</page-range>
            <pub-id pub-id-type="pmid">21265979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falutz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Potvin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mamputu</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Assaad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zoltowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Somero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moyle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martorell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grinspoon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-22</page-range>
            <pub-id pub-id-type="pmid">20101189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falutz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Allas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mamputu</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Potvin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kotler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Somero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richmond</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fessel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grinspoon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.</article-title>
            <source>AIDS</source>
            <year>2008</year>
            <month>Sep</month>
            <day>12</day>
            <volume>22</volume>
            <issue>14</issue>
            <fpage>1719</fpage>
            <page-range>1719-28</page-range>
            <pub-id pub-id-type="pmid">18690162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S140</fpage>
            <page-range>S140-S157</page-range>
            <pub-id pub-id-type="pmid">36507650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>6. Glycemic Targets: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S97</fpage>
            <page-range>S97-S110</page-range>
            <pub-id pub-id-type="pmid">36507646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S128</fpage>
            <page-range>S128-S139</page-range>
            <pub-id pub-id-type="pmid">36507637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Di Biagio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rusconi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cicalini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Abbraccio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>d'Ettorre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nunnari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sighinolfi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Spagnuolo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Squillace</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular risk and dyslipidemia among persons living with HIV: a review.</article-title>
            <source>BMC Infect Dis</source>
            <year>2017</year>
            <month>Aug</month>
            <day>09</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>551</fpage>
            <pub-id pub-id-type="pmid">28793863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sponseller</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kryzhanovski</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.</article-title>
            <source>Lancet HIV</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>7</issue>
            <fpage>e284</fpage>
            <page-range>e284-e294</page-range>
            <pub-id pub-id-type="pmid">28416195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grinspoon</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Fitch</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Zanni</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Fichtenbaum</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Umbleja</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Overton</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Malvestutto</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roa</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Diggs</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Fulda</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Paradis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Foldyna</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Looby</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Desvigne-Nickens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alston-Smith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leon-Cruz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCallum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ribaudo</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>PS</given-names>
              </name>
              <collab>REPRIEVE Investigators</collab>
            </person-group>
            <article-title>Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Aug</month>
            <day>24</day>
            <volume>389</volume>
            <issue>8</issue>
            <fpage>687</fpage>
            <page-range>687-699</page-range>
            <pub-id pub-id-type="pmid">37486775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fichtenbaum</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Tashima</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sprecher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glesby</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>Adult AIDS Clinical Trials Group Cardiovascular Subcommittee</collab>
              <collab>HIV Medical Association of the Infectious Disease Society of America</collab>
            </person-group>
            <article-title>Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.</article-title>
            <source>Clin Infect Dis</source>
            <year>2003</year>
            <month>Sep</month>
            <day>01</day>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>613</fpage>
            <page-range>613-27</page-range>
            <pub-id pub-id-type="pmid">12942391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das Pradhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fruchart</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>MacFadyen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zaharris</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amarenco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Eckel</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Elam</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Felicio</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Goudev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kodama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lorenzatti</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mankovsky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>P&#x000e1;ll</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Soran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Susekov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tendera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Paynter</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Buring</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ridker</surname>
                <given-names>PM</given-names>
              </name>
              <collab>PROMINENT Investigators</collab>
            </person-group>
            <article-title>Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>24</day>
            <volume>387</volume>
            <issue>21</issue>
            <fpage>1923</fpage>
            <page-range>1923-1934</page-range>
            <pub-id pub-id-type="pmid">36342113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Dhingra</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Ketchum</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Juliano</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Granowitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Budoff</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Tardif</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <collab>REDUCE-IT Investigators</collab>
            </person-group>
            <article-title>Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.</article-title>
            <source>Circulation</source>
            <year>2021</year>
            <month>Dec</month>
            <day>07</day>
            <volume>144</volume>
            <issue>23</issue>
            <fpage>1845</fpage>
            <page-range>1845-1855</page-range>
            <pub-id pub-id-type="pmid">34710343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rivkees</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>1343</fpage>
            <page-range>1343-1421</page-range>
            <pub-id pub-id-type="pmid">27521067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Shoback</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>1595</fpage>
            <page-range>1595-1622</page-range>
            <pub-id pub-id-type="pmid">30907953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shoback</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>105</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32068863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Clemmons</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Malozowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merriam</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Vance</surname>
                <given-names>ML</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>1587</fpage>
            <page-range>1587-609</page-range>
            <pub-id pub-id-type="pmid">21602453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>2. Classification and Diagnosis of Diabetes: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S15</fpage>
            <page-range>S15-S33</page-range>
            <pub-id pub-id-type="pmid">33298413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vodnala</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rubenfire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Secondary causes of dyslipidemia.</article-title>
            <source>Am J Cardiol</source>
            <year>2012</year>
            <month>Sep</month>
            <day>15</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>823</fpage>
            <page-range>823-5</page-range>
            <pub-id pub-id-type="pmid">22658245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Biller</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Zagar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Arafah</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Nippoldt</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mooradian</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scism-Bacon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chipman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency.</article-title>
            <source>J Bone Miner Res</source>
            <year>2007</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>762</fpage>
            <page-range>762-70</page-range>
            <pub-id pub-id-type="pmid">17280527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chanson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis.</article-title>
            <source>Circulation</source>
            <year>2003</year>
            <month>Nov</month>
            <day>25</day>
            <volume>108</volume>
            <issue>21</issue>
            <fpage>2648</fpage>
            <page-range>2648-52</page-range>
            <pub-id pub-id-type="pmid">14623813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johannsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ragnarsson</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Growth hormone deficiency in adults with hypopituitarism-What are the risks and can they be eliminated by therapy?</article-title>
            <source>J Intern Med</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>290</volume>
            <issue>6</issue>
            <fpage>1180</fpage>
            <page-range>1180-1193</page-range>
            <pub-id pub-id-type="pmid">34605087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Bunderen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Growth hormone deficiency and replacement therapy in adults: Impact on survival.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-133</page-range>
            <pub-id pub-id-type="pmid">33068227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Forrester</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spiegelman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Tchetgen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2002</year>
            <month>Oct</month>
            <day>01</day>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-6</page-range>
            <pub-id pub-id-type="pmid">12394802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsiodras</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mantzoros</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Samore</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.</article-title>
            <source>Arch Intern Med</source>
            <year>2000</year>
            <month>Jul</month>
            <day>10</day>
            <volume>160</volume>
            <issue>13</issue>
            <fpage>2050</fpage>
            <page-range>2050-6</page-range>
            <pub-id pub-id-type="pmid">10888979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Exploring Statins to Decrease HIV-Related Heart Disease Risk.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Aug</month>
            <day>18</day>
            <volume>314</volume>
            <issue>7</issue>
            <fpage>657</fpage>
            <page-range>657-9</page-range>
            <pub-id pub-id-type="pmid">26222872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teeraananchai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruxrungtham</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis.</article-title>
            <source>HIV Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>256</fpage>
            <page-range>256-266</page-range>
            <pub-id pub-id-type="pmid">27578404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcus</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Quesenberry</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Towner</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Horberg</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">27028501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwaku</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Myxedema coma.</article-title>
            <source>J Intensive Care Med</source>
            <year>2007</year>
            <season>Jul-Aug</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>224</fpage>
            <page-range>224-31</page-range>
            <pub-id pub-id-type="pmid">17712058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarlis</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Gourgiotis</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Thyroid emergencies.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2003</year>
            <month>May</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-36</page-range>
            <pub-id pub-id-type="pmid">12766540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flevaris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Basaria</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kalahasti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Snabes</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dubcenco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Travison</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <collab>TRAVERSE Study Investigators</collab>
            </person-group>
            <article-title>Cardiovascular Safety of Testosterone-Replacement Therapy.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Jul</month>
            <day>13</day>
            <volume>389</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-117</page-range>
            <pub-id pub-id-type="pmid">37326322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuen</surname>
                <given-names>KCJ</given-names>
              </name>
              <name>
                <surname>Biller</surname>
                <given-names>BMK</given-names>
              </name>
              <name>
                <surname>Radovick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jasim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pantalone</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.</article-title>
            <source>Endocr Pract</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1191</fpage>
            <page-range>1191-1232</page-range>
            <pub-id pub-id-type="pmid">31760824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149535.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harding</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pavkov</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Magliano</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gregg</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>Global trends in diabetes complications: a review of current evidence.</article-title>
            <source>Diabetologia</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-16</page-range>
            <pub-id pub-id-type="pmid">30171279</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
